0000200406-20-000026.txt : 20200414 0000200406-20-000026.hdr.sgml : 20200414 20200414080051 ACCESSION NUMBER: 0000200406-20-000026 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20200414 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200414 DATE AS OF CHANGE: 20200414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1229 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03215 FILM NUMBER: 20790084 BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 8-K 1 a2020q1cover.htm 8-K Document
false0000200406 0000200406 2020-04-14 2020-04-14 0000200406 jnj:A0.250NotesDue2022Member 2020-04-14 2020-04-14 0000200406 jnj:A1.650NotesDue2035Member 2020-04-14 2020-04-14 0000200406 jnj:A1.150NotesDue2028Member 2020-04-14 2020-04-14 0000200406 jnj:A0.650NotesDue2024Member 2020-04-14 2020-04-14 0000200406 jnj:A5.50NotesDue2024Member 2020-04-14 2020-04-14 0000200406 us-gaap:CommonStockMember 2020-04-14 2020-04-14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): 
April 14, 2020
Johnson & Johnson
 (Exact name of registrant as specified in its charter)
  
New Jersey
1-3215
22-1024240
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey  08933 
(Address of Principal Executive Offices)
 (Zip Code) 
Registrant's telephone number, including area code:
732-524-0400
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
☐             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
☐             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
               CFR 240.14d-2(b)) 
☐             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
               CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $1.00
JNJ
New York Stock Exchange
0.250% Notes Due January 2022
JNJ
New York Stock Exchange
0.650% Notes Due May 2024
JNJ
New York Stock Exchange
5.50% Notes Due November 2024
JNJ
New York Stock Exchange
1.150% Notes Due November 2028
JNJ
New York Stock Exchange
1.650% Notes Due May 2035
JNJ
New York Stock Exchange
 
 

 


Item 2.02                      Results of Operations and Financial Condition
 
On April 14, 2020, Johnson & Johnson issued the attached press release announcing its sales and earnings for the first quarter ended March 29, 2020.
 
Item 9.01            Financial Statements and Exhibits

(d)     Exhibits. 
 
Exhibit No.
 
Description of Exhibit
 
Press Release dated April 14, 2020 for the period ended March 29, 2020
 
Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the first quarter

104
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
 
 



 
 
 


 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
Johnson & Johnson
 
 
 
 
 (Registrant)
 
 
 
 
Date: 
April 14, 2020
By:
/s/ Robert J. Decker, Jr.
 
 
 
 
Robert J. Decker, Jr.
Controller
(Principal Accounting Officer)
 



 EX-99.1 2 a2020q1exhibit991.htm EXHIBIT 99.1 Exhibit


Exhibit 99.1

JOHNSON & JOHNSON REPORTS 2020 FIRST-QUARTER RESULTS:
•
Sales of $20.7 Billion reflecting strong growth of 3.3%, operational growth of 4.8%* and adjusted operational growth of 5.6%*, inclusive of the overall estimated negative impact of the COVID-19 pandemic
•
EPS of $2.17 increased 56.1%; adjusted EPS of $2.30 increased 9.5%*
•
Dividend increase of 6.3% announced
•
Long term fundamentals remain intact; 2020 Guidance lowered to reflect COVID-19 impact and related investments

New Brunswick, N.J. (April 14, 2020) - Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2020. The Company also announced earlier today that its Board of Directors declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. At the new rate, the indicated dividend on an annual basis is $4.04 per share compared to the previous rate of $3.80 per share.

“With Johnson & Johnson’s century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “Johnson & Johnson is built for times like this, and we are leveraging our scientific expertise, operational scale and financial strength in the effort to advance the work on our lead COVID-19 vaccine candidate. We are committed to beginning production at risk imminently and bringing an affordable and accessible vaccine to the public on a not-for-profit basis for emergency pandemic use.”

Mr. Gorsky continued, “I am both proud and amazed at the level of dedication that I have witnessed from our more than 132,000 employees as we have focused on delivering on our commitments and responsibilities to the patients and consumers we serve. Our strong performance in the first quarter reflects the efforts of our teams around the world and the sustainability of our business model. Today, our Board of Directors approved an increase in our quarterly dividend for the 58th consecutive year, underscoring our commitment to delivering value for our shareholders and the confidence we have in our business now and in the future.”
   
OVERALL FINANCIAL RESULTS:
q1chart1.jpg
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
4 Excludes intangible amortization expense and special items





REGIONAL SALES RESULTS:


regionalsales005.jpg

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded


SEGMENT SALES RESULTS:

a2020q1segments.jpg
1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 Excludes the impact of translational currency
3 Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded




  
SEGMENT COMMENTARY:

Consumer Health
Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 11.0%* driven primarily by over-the-counter products including TYLENOL and MOTRIN analgesics; upper respiratory products including ZYRTEC; digestive health products and ZARBEE’S NATURALS. Other contributors to growth were LISTERINE mouthwash in oral care products; NEUTROGENA and AVEENO in skin health/beauty products, as well as STAYFREE and o.b. in international women’s health. Consumer Health results across the majority of franchises were positively impacted by the increased demand related to the COVID-19 pandemic.

Pharmaceutical
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 10.2%* driven by STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, DARZALEX (daratumumab), for the treatment of multiple myeloma, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, OPSUMIT (macitentan), an oral endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension to delay disease progression, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. This growth was partially offset by biosimilar and generic competition, with declines primarily in international VELCADE (bortezomib), a proteasome inhibitor for the treatment of multiple myeloma, REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, and PROCRIT (epoetin alfa), a treatment for chemotherapy-induced anemia and patients with chronic kidney disease.

Medical Devices
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined by 4.8%* driven by the estimated net negative impact of the COVID-19 pandemic and the associated deferral of medical procedures to our Surgery, Orthopaedics, Interventional Solutions and Vision businesses.

 




NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:
The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases available online in the Investors section of the Company’s website at news releases.
Regulatory
Approvals

ERLEADA (apalutamide) - European Commission (EC) Approves Expanded Use for Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer
(press release)
STELARA (ustekinumab) - EC Approves Expanded Use for Treatment of Pediatric Patients With Moderate To Severe Plaque Psoriasis

(press release)
Regulatory
Submissions
Ponesimod - Submission of New Drug Applications to the U.S. Food and Drug Administration (FDA) and European Marketing Authorization for Treatment of Adults with Relapsing Multiple Sclerosis

(press release)
DARZALEX (daratumumab) - Submission to U.S. FDA for Combination with carfilzomib and dexamethasone (DKd) For Patients with Relapsed/Refractory Multiple Myeloma
 
Other
Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use; Announced

(press release)
XARELTO (rivaroxaban) -Landmark Phase 3 VOYAGER PAD Study of XARELTO Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
(press release)
Rilpivirine And Cabotegravir Results of Phase 3 FLARE Study Demonstrate the Safety and Efficacy of Long-Acting Injectable HIV Treatment Regimen through 96 Weeks
(press release)
Rilpivirine and Cabotegravir 48-week Results of Phase 3b ATLAS-2M Study Demonstrate the Safety and Efficacy of Long-Acting Injectable HIV Treatment Administered Every Two Months
(press release)
JNJ-6372 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Non-Small Cell Lung Cancer
(press release)
RPGR Gene Therapy Granted European Medicines Agency PRIME and Advanced Therapy Medicinal Product Designations for X-Linked Retinitis Pigmentosa
(press release)
HEARTLINE launched, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone® App and Apple Watch® Can Help Reduce the Risk of Stroke1

(press release)
1 iPhone and Apple Watch are trademarks of their respective owners





FULL-YEAR 2020 GUIDANCE:

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the Company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.
The impact of COVID-19, inclusive of the related investments the Company is making to combat the pandemic, is included in the guidance below.


 
April 2020
January 2020
($ in Billions, except EPS)    
Adjusted Operational Sales1,2
Change vs. Prior Year
(3.0%) - 0.5%
5.0% - 6.0%
Operational Sales2
Change vs. Prior Year
$79.2 to $82.2
(3.5%) - 0.0%
$85.8 to $86.6
4.5% - 5.5%
Estimated Reported Sales3
Change vs. Prior Year
$77.5 to $80.5
(5.5%) - (2.0%)
$85.4 to $86.2
4.0% - 5.0%
 
 
 
Adjusted Operational EPS (Diluted)2,4
Change vs. Prior Year
$7.65 to $80.5
(11.9%) - (7.3%)
$9.00 to $9.15
3.7% - 5.4%
Adjusted EPS (Diluted)3,4
Change vs. Prior Year
$7.50 to $7.90
(13.6%) - (9.0%)
$8.95 to $9.10
3.1% - 4.8%
1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 Non-GAAP financial measure; excludes the impact of translational currency
3 Calculated using Euro Average Rate: April 2020 = $1.09 Euro Average Rate: January 2020 = $1.11 (Illustrative purposes only)
4 Non-GAAP financial measure; excludes intangible amortization expense and special items

Other modeling considerations will be provided on the webcast.

WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the Company's website at events-and-presentations.

ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach




and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.
 
NON-GAAP FINANCIAL MEASURES:
*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the Company's website at quarterly-results.

Copies of the financial schedules accompanying this earnings release are available on the Company’s website at quarterly-results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investors section of the Company's website at quarterly-results.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the Company’s most recently filed Quarterly Report on Form 10-Q and the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.





 

Press Contacts:    Investor Contacts:

Cristal Downing        Christopher DelOrefice        Lisa Romanko
(732) 524-3283        (732) 524-2955            (732) 524-2034
(908) 616-8833 (M)

    


 EX-99.2 3 a2020q1exhibit992.htm EXHIBIT 99.2 Exhibit
Exhibit 99.2


Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
FIRST QUARTER
 
 
 
 
 
Percent Change
 
2020
 
2019
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
geographic area
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S.
 $ 10,699
 
  10,129
 
   5.6

%
            5.6

 
—

 
 
 
 
 
 
 
 
 
 
Europe
      4,827
 
    4,609
 
4.7

 
            7.5

 
(2.8
)
Western Hemisphere excluding U.S.
      1,502
 
    1,503
 
(0.1
)
 
            8.5

 
(8.6
)
Asia-Pacific, Africa
      3,663
 
    3,780
 
(3.1
)
 
(1.9
)
 
(1.2
)
International
      9,992
 
    9,892
 
   1.0

 
            4.0

 
(3.0
)
 
 
 
 
 
  
 
  
 
  
Worldwide
 $ 20,691
 
  20,021
 
   3.3

%
            4.8

 
(1.5
)
 
 
 
  
 
  
 
  
 
  
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.













Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 
Supplementary Sales Data
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Unaudited; Dollars in Millions)
FIRST QUARTER
 
 
 
 
 
 Percent Change
 
2020
 
2019
 
Total
 
Operations
 
Currency
Sales to customers by
 
 
 
 
 
 
 
 
 
segment of business
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consumer Health
 
 
 
 
 
 
 
 
 
    U.S.
 $ 1,740
 
    1,438
 
21.0

%
             21.0
 
—

    International
      1,885
 
    1,880
 
0.3

 
               3.9
 
(3.6
)
 
      3,625
   
    3,318
 
9.2

 
             11.3
 
(2.1
)
 
 
 
 
 
 
 
 
 
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
    U.S.
      6,061
 
    5,582
 
8.6

 
               8.6
 
—

    International
      5,073
 
    4,662
 
8.8

 
             12.0
 
(3.2
)
 
    11,134
   
  10,244
 
8.7

 
             10.1
 
(1.4
)
 
 
 
 
 
 
 
 
 
 
Medical Devices
 
 
 
 
 
 
 
 
 
    U.S.
      2,898
   
    3,109
 
(6.8
)
 
             (6.8)
 
—

    International
      3,034
 
    3,350
 
(9.4
)
 
             (6.9)
 
(2.5
)
 
      5,932
   
    6,459
 
(8.2
)
 
             (6.9)
 
(1.3
)
 
 
 
 
 
 
 
 
 
 
U.S.
    10,699
 
  10,129
 
5.6

 
               5.6
 
—

International
      9,992
 
    9,892
 
1.0

 
               4.0
 
(3.0
)
Worldwide
 $ 20,691
 
  20,021
 
3.3

%
               4.8
 
(1.5
)
 
   
 
 
 
 
 
 
 
 
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.




Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
 

Condensed Consolidated Statement of Earnings
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
(Unaudited; in Millions Except Per Share Figures)
FIRST QUARTER
 
 
 
 
 
 
 
 
 
 
 
2020
 
2019
 
Percent

 
 
 
Percent
 
 
 
Percent
 
Increase

 
Amount
 
to Sales
 
Amount
 
to Sales
 
(Decrease)

Sales to customers
 $ 20,691

 
     100.0

 
 $ 20,021

 
     100.0

 
3.3

Cost of products sold
      7,062

 
       34.1

 
      6,615

 
       33.0

 
6.8

Gross Profit
    13,629

 
65.9

 
    13,406

 
67.0

 
1.7

Selling, marketing and administrative expenses
      5,203

 
       25.1

 
      5,219

 
       26.1

 
(0.3
)
Research and development expense
      2,580

 
       12.5

 
      2,858

 
       14.3

 
(9.7
)
In-process research and development
—

 
—

 
         890

 
         4.4

 
 
Interest (income) expense, net
(42
)
 
(0.2
)
 
             3

 
         0.0

 
 
Other (income) expense, net
(679
)
 
(3.3
)
 
(22
)
 
(0.1
)
 
 
Restructuring
           58

 
         0.3

 
           36

 
         0.2

 
 
Earnings before provision for taxes on income
      6,509

 
       31.5

 
      4,422

 
       22.1

 
47.2

Provision for taxes on income
         713

 
         3.5

 
         673

 
         3.4

 
5.9

Net earnings
      5,796

 
       28.0

 
      3,749

 
       18.7

 
54.6

 
 
 
 
 
 
 
 
 
 
Net earnings per share (Diluted)
 $ 2.17

 
 
 
 $ 1.39

 
 
 
56.1

 
 
 
 
 
 
 
 
 
 
Average shares outstanding (Diluted)
2,671.0

 
 
 
2,698.8

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effective tax rate
11.0

%
 
 
15.2

%
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted earnings before provision for taxes and net earnings (1) (A)
 
 
 
 
 
 
 
 
 
Earnings before provision for taxes on income
 $ 7,244

 
35.0

 
 $ 6,867

 
34.3

 
5.5

Net earnings
 $ 6,154

 
29.7

 
 $ 5,661

 
28.3

 
8.7

Net earnings per share (Diluted)
 $ 2.30

 
 
 
 $ 2.10

 
 
 
9.5

Effective tax rate
15.0

%
 
 
17.6

%
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) See Reconciliation of Non-GAAP Financial Measures.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.






Johnson & Johnson and Subsidiaries
 
 
 
 
Reconciliation of Non-GAAP Financial Measures
 
 
 
 
 
 
 
First Quarter
 
(Dollars in Millions Except Per Share Data)
 
2020
 
2019
 
Net Earnings, after tax- as reported
 
$5,796

 
$3,749

 
 
 
 
 
 
 
Pre-tax Adjustments
 
 
 
 
 
Intangible Asset Amortization expense
 
1,118

 
1,130

 
Litigation expense
 
120

 
423

 
IPR&D
 
—

 
890

 
Restructuring related
 
118

 
90

 
Acquisition and Integration related 1
 
(962
)
 
67

 
Unrealized (gains)/losses on securities
 
327

 
(158
)
 
Medical Device Regulation 2
 
14

 
—

 
Other
 
—

 
3

 
 
 
 
 
 
 
Tax Adjustments
 
 
 
 
 
Tax impact on special item adjustments 3
 
(267
)
 
(533
)
 
Tax legislation and related impacts
 
(110
)
 
—

 
Adjusted Net Earnings, after tax
 
$6,154

 
$5,661

 
Average shares outstanding (Diluted)
 
2,671.0

 
2,698.8

 
Adjusted net earnings per share (Diluted)
 
$2.30

 
$2.10

 
Operational adjusted net earnings per share (Diluted)
 
$2.32

 
 
 
 
 
 
 
 
 
Notes:
 
 
 
 
 
1 Acquisition and integration related costs for the first quarter of 2020 primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition.
 
2 European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing performance.
 
3 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.






Johnson & Johnson and Subsidiaries
 
 
 
 
 
 
 
 
Reconciliation of Non-GAAP Financial Measure
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adjusted Operational Sales Growth (A)
 FIRST QUARTER 2020 ACTUAL vs. 2019 ACTUAL
 
 Segments
 
 
 Consumer Health
 
 Pharmaceutical
 
 Medical Devices
 
 Total
 WW As Reported
 
9.2%
 
8.7%
 
(8.2)%
 
3.3%
 U.S.
 
21.0%
 
8.6%
 
(6.8)%
 
5.6%
 International
 
0.3%
 
8.8%
 
(9.4)%
 
1.0%
 
 
 
 
 
 
 
 
 
 WW Currency
 
(2.1)
 
(1.4)
 
(1.3)
 
(1.5)
 U.S.
 
—
 
—
 
—
 
—
 International
 
(3.6)
 
(3.2)
 
(2.5)
 
(3.0)
 
 
 
 
 
 
 
 
 
 WW Operational
 
11.3%
 
10.1%
 
(6.9)%
 
4.8%
 U.S.
 
21.0%
 
8.6%
 
(6.8)%
 
5.6%
 International
 
3.9%
 
12.0%
 
(6.9)%
 
4.0%
 
 
 
 
 
 
 
 
 
Skin Health / Beauty
 
 
 
 
 
 
 
 
Dr. Ci Labo - Japan
 
(0.4)
 
 
 
 
 
(0.1)
 U.S.
 
0.0
 
 
 
 
 
0.0
 International
 
(0.7)
 
 
 
 
 
(0.1)
 
 
 
 
 
 
 
 
 
General Surgery
 
 
 
 
 
 
 
 
Advanced Sterilization Products
 
 
 
 
 
2.1
 
0.8
 U.S.
 
 
 
 
 
2.7
 
0.9
 International
 
 
 
 
 
1.6
 
0.6
 
 
 
 
 
 
 
 
 
Baby Care
 
 
 
 
 
 
 
 
Baby Center
 
0.3
 
 
 
 
 
0.0
 U.S.
 
0.8
 
 
 
 
 
0.1
 International
 
0.0
 
 
 
 
 
0.0
 
 
 
 
 
 
 
 
 
All Other Acquisitions and Divestitures
 
(0.2)
 
0.1
 
(0.1)
 
0.0
 U.S.
 
0.0
 
0.1
 
(0.2)
 
0.0
 International
 
(0.3)
 
0.0
 
0.1
 
0.0
 
 
 
 
 
 
 
 
 
WW Adjusted Operational
 
11.0%
 
10.2%
 
(4.8)%
 
5.6%
 U.S.
 
21.7%
 
8.7%
 
(4.3)%
 
6.7%
 International
 
2.8%
 
12.0%
 
(5.3)%
 
4.5%
 
 
 
 
 
 
 
 
 
Note: Percentages are based on actual, non-rounded figures and may not sum
 
 
 
 
 
 
 
 
 
 
 
(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.








Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2020
 
2019
 
Reported
Operational (1)
Currency

CONSUMER HEALTH SEGMENT (2) (3)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BABY CARE
 
 
 
 
 
 
 
 
 
US
 
$
92

 
87

 
6.7
 %
6.7
 %
—
 %
Intl
 
 
269

 
307

 
(12.4
)
(8.2
)
(4.2
)
WW
 
 
361

 
394

 
(8.2
)
(4.9
)
(3.3
)
 
 
 
 
 
 
 
 
 
 
SKIN HEALTH / BEAUTY (4)
 
 
 
 
 
 
 
 
 
US
 
 
659

 
588

 
12.1

12.1

—

Intl
 
 
458

 
502

 
(8.8
)
(6.5
)
(2.3
)
WW
 
 
1,117

 
1,090

 
2.5

3.5

(1.0
)
 
 
 
 
 
 
 
 
 
 
ORAL CARE
 
 
 
 
 
 
 
 
 
US
 
 
176

 
151

 
16.2

16.2

—

Intl
 
 
219

 
216

 
1.5

5.3

(3.8
)
WW
 
 
395

 
367

 
7.6

9.8

(2.2
)
 
 
 
 
 
 
 
 
 
 
OTC
 
 
 
 
 
 
 
 
 
US
 
 
689

 
507

 
35.9

35.9

—

Intl
 
 
659

 
580

 
13.7

17.0

(3.3
)
WW
 
 
1,348

 
1,087

 
24.1

25.8

(1.7
)
 
 
 
 
 
 
 
 
 
 
WOMEN'S HEALTH
 
 
 
 
 
 
 
 
 
US
 
 
4

 
3

 
32.0

32.0

—

Intl
 
 
228

 
222

 
2.5

8.9

(6.4
)
WW
 
 
232

 
225

 
2.9

9.2

(6.3
)
 
 
 
 
 
 
 
 
 
 
WOUND CARE / OTHER
 
 
 
 
 
 
 
 
 
US
 
 
119

 
102

 
17.0

17.0

—

Intl
 
 
52

 
53

 
(1.2
)
1.9

(3.1
)
WW
 
 
171

 
155

 
10.7

11.8

(1.1
)
 
 
 
 
 
 
 
 
 
 
TOTAL CONSUMER HEALTH
 
 
 
 
 
 
 
 
 
US
 
 
1,740

 
1,438

 
21.0

21.0

—

Intl
 
 
1,885

 
1,880

 
0.3

3.9

(3.6
)
WW
 
$
3,625

 
3,318

 
9.2
 %
11.3
 %
(2.1
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 





Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2020
 
2019
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IMMUNOLOGY
 
 
 
 
 
 
 
 
 
US
 
$
2,410

 
2,163

 
11.4
 %
11.4
 %
—
 %
Intl
 
 
1,228

 
1,088

 
12.8

16.3

(3.5
)
WW
 
 
3,638

 
3,251

 
11.9

13.1

(1.2
)
     REMICADE
 
 
 
 
 
 
 
 
 
     US
 
 
625

 
774
 
(19.3
)
(19.3
)
—

     US Exports (5)
 
 
110

 
76

 
44.3

44.3

—

     Intl
 
 
256

 
252

 
1.5

5.2

(3.7
)
     WW
 
 
990

 
1,102

 
(10.2
)
(9.3
)
(0.9
)
     SIMPONI / SIMPONI ARIA
 
 
 
 
 
 
 
 
 
     US
 
 
272

 
263

 
3.4

3.4

—

     Intl
 
 
258

 
261

 
(1.2
)
2.6

(3.8
)
     WW
 
 
529

 
524

 
1.1

3.0

(1.9
)
     STELARA
 
 
 
 
 
 
 
 
 
     US
 
 
1,217

 
882

 
37.9

37.9

—

     Intl
 
 
603

 
523

 
15.2

18.3

(3.1
)
     WW
 
 
1,819

 
1,405

 
29.5

30.6

(1.1
)
     TREMFYA
 
 
 
 
 
 
 
 
 
     US
 
 
187

 
168

 
11.5

11.5

—

     Intl
 
 
109

 
49

 
*

*

*

     WW
 
 
296

 
217

 
36.4

37.3

(0.9
)
     OTHER IMMUNOLOGY
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
3

 
3

 
(6.9
)
(5.6
)
(1.3
)
     WW
 
 
3

 
3

 
(6.9
)
(5.6
)
(1.3
)
 
 
 
 
 
 
 
 
 
 
INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
US
 
 
436

 
357

 
22.3

22.3

—

Intl
 
 
483

 
489

 
(1.2
)
2.7

(3.9
)
WW
 
 
920

 
846

 
8.7

11.0

(2.3
)
     EDURANT / rilpivirine
 
 
 
 
 
 
 
 
 
     US
 
 
12

 
12

 
0.6

0.6

—

     Intl
 
 
212

 
199

 
6.4

9.2

(2.8
)
     WW
 
 
224

 
211

 
6.1

8.7

(2.6
)
     PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
 
 
 
 
 
 
     US
 
 
396

 
315

 
25.5

25.5

—

     Intl
 
 
184

 
208

 
(11.6
)
(6.4
)
(5.2
)
     WW
 
 
579

 
523

 
10.8

12.8

(2.0
)
     OTHER INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
     US
 
 
29

 
30

 
(3.4
)
(3.4
)
—

     Intl
 
 
87

 
82

 
6.7

10.2

(3.5
)
     WW
 
 
116

 
112

 
4.0

6.6

(2.6
)
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 




Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2020
 
2019
 
Reported
Operational (1)
Currency

PHARMACEUTICAL SEGMENT  (2) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NEUROSCIENCE
 
 
 
 
 
 
 
 
 
US
 
$
748

 
723

 
3.3
 %
3.3
 %
—
 %
Intl
 
 
910

 
905

 
0.5

3.0

(2.5
)
WW
 
 
1,658

 
1,629

 
1.8

3.1

(1.3
)
     CONCERTA / methylphenidate
 
 
 
 
 
 
 
 
 
     US
 
 
52

 
97

 
(46.1
)
(46.1
)
—

     Intl
 
 
118

 
116

 
1.5

3.6

(2.1
)
     WW
 
 
171

 
214

 
(20.1
)
(19.0
)
(1.1
)
     INVEGA SUSTENNA / XEPLION / INVEGA
 
 
 
 
 
     TRINZA / TREVICTA
 
 
 
 
 
 
 
 
 
     US
 
 
544

 
483

 
12.6

12.6

—

     Intl
 
 
339

 
307

 
10.3

13.2

(2.9
)
     WW
 
 
883

 
790

 
11.7

12.9

(1.2
)
     RISPERDAL CONSTA
 
 
 
 
 
 
 
 
 
     US
 
 
76

 
77

 
(0.3
)
(0.3
)
—

     Intl
 
 
94

 
102

 
(8.7
)
(5.9
)
(2.8
)
     WW
 
 
170

 
179

 
(5.1
)
(3.5
)
(1.6
)
     OTHER NEUROSCIENCE
 
 
 
 
 
 
 
 
 
     US
 
 
75

 
66

 
12.5

12.5

—

     Intl
 
 
360

 
379

 
(5.1
)
(3.1
)
(2.0
)
     WW
 
 
435

 
446

 
(2.5
)
(0.8
)
(1.7
)
 
 
 
 
 
 
 
 
 
 
ONCOLOGY
 
 
 
 
 
 
 
 
 
US
 
 
1,175

 
962

 
22.1

22.1

—

Intl
 
 
1,839

 
1,556

 
18.2

21.7

(3.5
)
WW
 
 
3,013

 
2,518

 
19.7

21.8

(2.1
)
     DARZALEX
 
 
 
 
 
 
 
 
 
     US
 
 
463

 
352

 
31.8

31.8

—

     Intl
 
 
474

 
277

 
70.9

76.8

(5.9
)
     WW
 
 
937

 
629

 
49.0

51.6

(2.6
)
     ERLEADA (6)
 
 
 
 
 
 
 
 
 
     US
 
 
119

 
58

 
*

*

—

     Intl
 
 
24

 
3

 
*

*

*

     WW
 
 
143

 
61

 
*

*

*

     IMBRUVICA
 
 
 
 
 
 
 
 
 
     US
 
 
432

 
349

 
23.9

23.9

—

     Intl
 
 
599

 
435

 
37.8

42.3

(4.5
)
     WW
 
 
1,031

 
784

 
31.6

34.1

(2.5
)
     VELCADE
 
 
 
 
 
 
 
 
 
     US
 
 
—

 
—

 
—

—

—

     Intl
 
 
108

 
263

 
(59.0
)
(58.2
)
(0.8
)
     WW
 
 
108

 
263

 
(59.0
)
(58.2
)
(0.8
)
     ZYTIGA / abiraterone acetate
 
 
 
 
 
 
 
 
 
     US
 
 
139

 
185

 
(25.2
)
(25.2
)
—

     Intl
 
 
552

 
494

 
11.7

14.3

(2.6
)
     WW
 
 
690

 
679

 
1.6

3.5

(1.9
)
     OTHER ONCOLOGY (6)
 
 
 
 
 
 
 
 
 
     US
 
 
22

 
18

 
20.1

20.1

—

     Intl
 
 
82

 
84

 
(2.7
)
0.6

(3.3
)
     WW
 
 
104

 
102

 
1.3

4.1

(2.8
)
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2020
 
2019
 
Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT  (2) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
PULMONARY HYPERTENSION
 
 
 
 
 
 
US
 
$
486

 
430

 
13.0
 %
13.0
 %
—
 %
Intl
 
 
260

 
226

 
14.9

17.8

(2.9
)
WW
 
 
745

 
656

 
13.7

14.7

(1.0
)
     OPSUMIT
 
 
 
 
 
 
 
 
 
     US
 
 
229

 
172

 
33.0

33.0

—

     Intl
 
 
160

 
133

 
20.2

23.3

(3.1
)
     WW
 
 
389

 
306

 
27.4

28.8

(1.4
)
     UPTRAVI
 
 
 
 
 
 
 
 
 
     US
 
 
212

 
176

 
20.7

20.7

—

     Intl
 
 
38

 
22

 
70.2

75.0

(4.8
)
     WW
 
 
250

 
198

 
26.2

26.8

(0.6
)
     OTHER PULMONARY HYPERTENSION (6)
 
 
 
 
 
 
 
     US
 
 
44

 
82

 
(45.9
)
(45.9
)
—

     Intl
 
 
62

 
71

 
(12.4
)
(10.7
)
(1.7
)
     WW
 
 
106

 
152

 
(30.4
)
(29.6
)
(0.8
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2020
 
2019
 
Reported
Operational (1)
Currency
PHARMACEUTICAL SEGMENT  (2) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
CARDIOVASCULAR / METABOLISM / OTHER
 
 
 
 
 
 
US
 
$
806

 
947

 
(14.9
)%
(14.9
)%
—
 %
Intl
 
 
354

 
398

 
(11.0
)
(8.7
)
(2.3
)
WW
 
 
1,160

 
1,345

 
(13.8
)
(13.1
)
(0.7
)
     XARELTO
 
 
 
 
 
 
 
 
 
     US
 
 
527

 
542

 
(2.7
)
(2.7
)
—

     Intl
 
 
—

 
—

 
—

—

—

     WW
 
 
527

 
542

 
(2.7
)
(2.7
)
—

     INVOKANA / INVOKAMET
 
 
 
 
 
 
 
 
 
     US
 
 
117

 
154

 
(23.6
)
(23.6
)
—

     Intl
 
 
58

 
49

 
18.6

20.9

(2.3
)
     WW
 
 
175

 
202

 
(13.5
)
(12.9
)
(0.6
)
     PROCRIT / EPREX
 
 
 
 
 
 
 
 
 
     US
 
 
76

 
148

 
(48.5
)
(48.5
)
—

     Intl
 
 
79

 
78

 
0.4

1.9

(1.5
)
     WW
 
 
155

 
226

 
(31.6
)
(31.0
)
(0.6
)
     OTHER
 
 
 
 
 
 
 
 
 
     US
 
 
85

 
104

 
(18.0
)
(18.0
)
—

     Intl
 
 
217

 
271

 
(19.7
)
(17.1
)
(2.6
)
     WW
 
 
302

 
374

 
(19.2
)
(17.4
)
(1.8
)
 
 
 
 
 
 
 
 
 
 
TOTAL PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
US
 
 
6,061

 
5,582

 
8.6

8.6

—

Intl
 
 
5,073

 
4,662

 
8.8

12.0

(3.2
)
WW
 
$
11,134

 
10,244

 
8.7
 %
10.1
 %
(1.4
)%
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 



Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2020
 
2019
 
Reported
Operational (1)
Currency

MEDICAL DEVICES SEGMENT (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
INTERVENTIONAL SOLUTIONS
 
 
 
 
 
 
 
 
 
US
 
 
365

 
343

 
6.6
 %
6.6
 %
—
 %
Intl
 
 
362

 
389

 
(6.9
)
(5.1
)
(1.8
)
WW
 
 
727

 
732

 
(0.6
)
0.4

(1.0
)
 
 
 
 
 
 
 
 
 
 
ORTHOPAEDICS
 
 
 
 
 
 
 
 
 
US
 
 
1,250

 
1,318

 
(5.2
)
(5.2
)
—

Intl
 
 
788

 
885

 
(11.0
)
(8.5
)
(2.5
)
WW
 
 
2,038

 
2,204

 
(7.5
)
(6.5
)
(1.0
)
 
 
 
 
 
 
 
 
 
 
     HIPS
 
 
 
 
 
 
 
 
 
     US
 
 
206

 
213

 
(3.6
)
(3.6
)
—

     Intl
 
 
132

 
148

 
(11.2
)
(8.4
)
(2.8
)
     WW
 
 
337

 
361

 
(6.7
)
(5.6
)
(1.1
)
 
 
 
 
 
 
 
 
 
 
     KNEES
 
 
 
 
     US
 
 
214

 
223

 
(4.2
)
(4.2
)
—

     Intl
 
 
130

 
146

 
(11.4
)
(8.9
)
(2.5
)
     WW
 
 
343

 
369

 
(7.0
)
(6.1
)
(0.9
)
 
 
 
 
 
 
 
 
 
 
     TRAUMA
 
 
 
 
 
 
 
 
 
     US
 
 
407

 
417

 
(2.3
)
(2.3
)
—

     Intl
 
 
247

 
268

 
(8.0
)
(5.3
)
(2.7
)
     WW
 
 
654

 
685

 
(4.5
)
(3.5
)
(1.0
)
 
 
 
 
 
 
 
 
 
 
     SPINE, SPORTS & OTHER (7)
 
 
     US
 
 
423

 
465

 
(8.9
)
(8.9
)
—

     Intl
 
 
280

 
323

 
(13.3
)
(11.1
)
(2.2
)
     WW
 
 
703

 
788

 
(10.7
)
(9.8
)
(0.9
)
 
 
 
 
 
 
 
 
 
 
See footnotes at end of schedule
 
 
 
 
 
 
 
 
 


Johnson & Johnson
Segment Sales
(Dollars in Millions)
 
 
 
 
 
 
 
 
 
 
 
 
 
FIRST QUARTER
 
 
 
 
 
 
 
% Change
 
 
 
2020
 
2019
 
Reported
Operational (1)
Currency

MEDICAL DEVICES SEGMENT (2) (Continued)
 
 
 
 
 
 
 
 
 
 
 
 
 
SURGERY
 
 
 
 
 
 
US
 
$
844

 
1,001

 
(15.7
)%
(15.7
)%
—
 %
Intl
 
 
1,257

 
1,394

 
(9.8
)
(6.7
)
(3.1
)
WW
 
 
2,100

 
2,395

 
(12.3
)
(10.5
)
(1.8
)
 
 
 
 
 
 
 
 
 
 
     ADVANCED
 
 
 
 
 
 
 
 
 
     US
 
 
381

 
404

 
(5.7
)
(5.7
)
—

     Intl
 
 
567

 
576

 
(1.6
)
1.6

(3.2
)
     WW
 
 
948

 
980

 
(3.3
)
(1.4
)
(1.9
)
 
 
 
 
 
 
 
 
 
 
     GENERAL (6)
 
 
 
 
 
 
 
 
 
     US
 
 
463

 
597

 
(22.5
)
(22.5
)
—

     Intl
 
 
690

 
818

 
(15.7
)
(12.6
)
(3.1
)
     WW
 
 
1,153

 
1,414

 
(18.5
)
(16.8
)
(1.7
)
 
 
 
 
 
 
 
 
 
 
VISION
 
 
 
 
US
 
 
439

 
446

 
(1.6
)
(1.6
)
—

Intl
 
 
628

 
682

 
(8.0
)
(6.4
)
(1.6
)
WW
 
 
1,067

 
1,129

 
(5.5
)
(4.5
)
(1.0
)
 
 
 
 
 
 
 
 
 
 
     CONTACT LENSES / OTHER
 
 
 
 
 
 
 
 
 
     US
 
 
346

 
321

 
7.7

7.7

—

     Intl
 
 
467

 
502

 
(7.0
)
(5.4
)
(1.6
)
     WW
 
 
814

 
824

 
(1.3
)
(0.3
)
(1.0
)
     SURGICAL
 
 
 
 
 
 
 
 
 
     US
 
 
93

 
125

 
(25.5
)
(25.5
)
—

     Intl
 
 
160

 
180

 
(11.0
)
(9.2
)
(1.8
)
     WW
 
 
253

 
305

 
(16.9
)
(15.9
)
(1.0
)
 
 
 
 
 
 
 
 
 
 
TOTAL MEDICAL DEVICES
 
 
US
 
 
2,898

 
3,109

 
(6.8
)
(6.8
)
—

Intl
 
 
3,034

 
3,350

 
(9.4
)
(6.9
)
(2.5
)
WW
 
$
5,932

 
6,459

 
(8.2
)%
(6.9
)%
(1.3
)%
 
 
 
 
 
 
 
 
 
 
Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-
rounded figures and, therefore, may not recalculate precisely.
 
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
 
 
(2) Unaudited
 
 
 
 
 
 
 
 
 
(3) Previously referred to as Consumer
 
 
 
 
 
 
 
 
 
(4) Previously referred to as Beauty
 
(5) Reported as U.S. sales
(6) Refer to supplemental schedule
(7) Previously referred to as Spine & Other





Johnson & Johnson
Supplemental Sales Information
(Dollars in Millions)
Prior quarter amounts have been reclassified to
 
 
 
 
 
 
 
 
 
 
 
conform to current quarter products disclosure
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2018
 
2019
 
2019
 
Full Year
 
Q1
 
Q2
 
Q3
 
Q4
 
Full Year
PHARMACEUTICAL SEGMENT (1)
 
 
 
 
 
 
 
 
 
 
 
     ERLEADA (2)
 
 
 
 
 
 
 
 
 
 
 
     US
         124

 
           58
 
           62
 
           74
 
         103
 
            297
     Intl
—

 
             3
 
             7
 
           12
 
           13
 
              35
     WW
         124

 
           61
 
           69
 
           86
 
         116
 
            332
 
 
 
 
 
 
 
 
 
 
 
 
     OTHER ONCOLOGY (2)
 
 
 
 
 
 
 
 
 
 
 
     US
         104

 
           18
 
           16
 
           17
 
           19
 
              70
     Intl
         362

 
           84
 
           85
 
           83
 
           84
 
            336
     WW
         466

 
         102
 
         101
 
         100
 
         104
 
            407
 
 
 
 
 
 
 
 
 
 
 
 
PULMONARY HYPERTENSION
 
 
 
 
 
 
 
 
 
 
 
     OTHER PAH (3)
 
 
 
 
 
 
 
 
 
 
 
     US
         353

 
           82
 
           61
 
           36
 
           26
 
            205
     Intl
         342

 
           71
 
           78
 
           61
 
           62
 
            272
     WW
         695

 
         152
 
         140
 
           96
 
           88
 
            476
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEDICAL DEVICES SEGMENT (1)
 
 
 
 
 
 
 
 
 
 
 
     GENERAL SURGERY (4)
 
 
 
 
 
 
 
 
 
 
 
     US
      2,468

 
         597
 
         530
 
         531
 
         534
 
         2,192
     Intl
      3,431

 
         818
 
         794
 
         769
 
         834
 
         3,215
     WW
      5,899

 
      1,414
 
      1,325
 
      1,301
 
      1,366
 
         5,406
 
 
 
 
 
 
 
 
 
 
 
 
Note: Columns and rows within tables may not add due to rounding. 
 
 
 
 
 
 
 
 
 
 
 
 
(1) Unaudited
 
 
 
 
 
 
 
 
 
 
 
(2) ERLEADA was previously included in Other Oncology
 
 
 
 
 
 
 
(3) Other PAH is inclusive of TRACLEER, which was previously disclosed separately
(4) General Surgery is inclusive of Specialty Surgery, which was previously disclosed separately



 EX-101.SCH 4 jnj-20200413.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 jnj-20200413_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 6 jnj-20200413_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 7 jnj-20200413_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover page. Entities [Table] Entities [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock, Par Value $1.00 Common Stock [Member] 0.250% Notes Due January 2022 0.250% Notes Due 2022 [Member] 0.250% Notes Due 2022 [Member] 0.650% Notes Due May 2024 0.650% Notes Due 2024 [Member] 0.650% Notes Due 2024 [Member] 5.50% Notes Due November 2024 5.50% Notes Due 2024 [Member] 5.50% Notes Due 2024 [Member] 1.150% Notes Due November 2028 1.150% Notes Due 2028 [Member] 1.150% Notes Due 2028 [Member] 1.650% Notes Due May 2035 1.650% Notes Due 2035 [Member] 1.650% Notes Due 2035 [Member] Entity Information [Line Items] Entity Information [Line Items] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 8 jnj-20200413_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 9 a2020q1segments.jpg SEGMENTSQ12020 begin 644 a2020q1segments.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1$*17AI9@ 34T *@ @ ! $[ ( M 5 (2H=I 0 ! (8)R= $ J 0V.H< < @, /@ M '!A8VME="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ MDY48WIK8SED)S\^#0H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS M.FUE=&$O(CX\"UN&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT M'!A8VME="!E;F0])W7J#A(6&AXB)BI*3E)66EYB9FJ*C MI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ M\O/T]?;W^/GZ_\0 'P$ P$! 0$! 0$! 0 $" P0%!@<("0H+_\0 MM1$ @$"! 0#! <%! 0 0)W $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'! M"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=8 M65IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ M_]H # ,! (1 Q$ /P#Z1HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH *XSXB>+KOPK_82VE[I>GQZEJ'V6>]U2,O% GE.^[ DC[J! MRW>NSK"\0>&O[=U70;W[7Y']CWQO-GE[O._=NFW.1M^_G//3I2ZKU7YZAT?H MS+;Q5?P>+-!TCSM/OH-0TJYO);NWB95D:/R]IC&]@$(&*[O4?"_V_QIIVO_ &SR M_L5E<6GD>5G?YI0[MV>,;.F#G/:L'1OAC_8;>%;BPU;9>Z# ]I<3BVP+^V;) M,3+O^7#88'+8(Z.M$=E?M^.G_!_JP2U>G?\-?^!_5S/U'7]9O_ !K/X;\--8VKV-FEU=W= M] \ZYD9@D:QJZ'^!B6W<<#!K)T#XBW^M>(]"TR6RM[=KK^T(=00%G,<]JRK^ M[;(!4Y)Y&>1Z5J>)/!5[J6KW&K>'-=;1+^[M!9W,GVU;4Q?36-E JL(Y)1<&&($;B3 MDX)P?7&*IWWQ.OE\$>&=52;2])N=1U'^SM2EU&-FALI$$@EX\Q,8>/C+=#6D MWPLAFT30-)N-7N&L],OI-0NO*#0R7D[%V!#HX,0#N6&,G@#/&:CL_A4FGZE' M)::S-]AAUU=9BMIT>9U?RBDB&5Y"S;B=VX\CGKG-"[/R_"U_OU^Y"?=>?ZV_ M0F\/>)_$'B/P_K$UE>:09=.O&BM]4CLI)+2^B"!MR)YP/4[#?^$7L MM7TZTOM^EWES)/9VGD[?L(D&7C4[N5W$L!@8R1S64?AS=0>$/"FD:?K4,5SX M:GCFCN9[$R).41DP8Q(I ._/WNU'_P!K_P#;?U]P?_;?_:_U]Y7\2>.;W1/# M?A^\MO$'AVX75-2%K+K!@;[&D960[PHG[% ,F3'7I6QX"\3WOB6UU-KUK.ZC ML[UK>WU&PC9+>]3:IWH&9NA)4X9AD<&I=1\+:AK?]@RZQJEJUUI.I"^9[6R: M))@$=0FUI6*_?Z[CTZ5)X0\)_P#"()J5I:7OFZ7<7C7-G9^5M^Q!^7C4Y.5W M9(&!C)ZTUUO_ %M_P?ZL#Z6_K?\ X']7.CHHHI %%%5M0U*QTBPDOM5O+>QM M(L>9<7,JQQID@#+,0!DD#ZF@"S17-_\ "Q_!'_0Y>'__ :0?_%4?\+'\$?] M#EX?_P#!I!_\50!TE%'_\ P:0?_%4 =)17 M-_\ "Q_!'_0Y>'__ :0?_%4?\+'\$?]#EX?_P#!I!_\50!TE%'_\ P:0?_%4 =)17-_\ "Q_!'_0Y>'__ :0?_%4?\+' M\$?]#EX?_P#!I!_\50!TE%'_\ P:0?_%4 M=)7FZ_$J[C\8:UI-ZEC;P6<#)/&3CI65JFN>%F\32Z]X<^)'AK3+VZM5M;H7%Q# M13>_]=A=//\ X/\ D:'B7QWJOA;6]!M+W25NQ=V% MU#M6O],N[KXEZ'+-8Z==63R2WEMNG,Z*ID M.UU5<;6&/WE^ M;/J#S0O/^OB_^U^\:M_7R_X)Z3<_$W2+7Q%+I+V6HMY-_;V$EXL2&%99T#1< M[]Q!SC(7@]<#!I(/B?I%QKUKIR66H"&[NKFU@U!HX_L\CVZEI3G?N &TC)49 M(.,@$UR%S#X)N;^ZNF^)/AY3<:O8ZF5%U!A?LR*NS_6_Q;TW4M0NHB=9M&$D=PCJ '$N]FS(3AHTV@D9?@T=+=?^ OU MN+I=_P!;_P# /7= \?:7XAU*"SM[:]MC>6S7EA+'"M@ M@XQ745X_X)M_A_X-U"*>+QMX,ECM;=K>W:WCLX+AP3]Z:?>S2-@8RNP'DD'M MWG_"Q_!'_0Y>'_\ P:0?_%4W:V@M;LZ2BN;_ .%C^"/^AR\/_P#@T@_^*H_X M6/X(_P"AR\/_ /@T@_\ BJ0SI**YO_A8_@C_ *'+P_\ ^#2#_P"*H_X6/X(_ MZ'+P_P#^#2#_ .*H Z2BN;_X6/X(_P"AR\/_ /@T@_\ BJ/^%C^"/^AR\/\ M_@T@_P#BJ .DHKF_^%C^"/\ H"/^A-\/_\ @K@_^)KI** .;_X5QX(_ MZ$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)KI** .;_X5QX(_Z$WP_P#^ M"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)KI** .;_X5QX(_Z$WP_P#^"N#_ .)H M_P"%<>"/^A-\/_\ @K@_^)KI** .;_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/ M^A-\/_\ @K@_^)KI** .;_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\ M@K@_^)KI** .;_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)KI M** .;_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)KI** .;_X5 MQX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)KI** .;_X5QX(_Z$WP M_P#^"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)KI** .;_X5QX(_Z$WP_P#^"N#_ M .)H_P"%<>"/^A-\/_\ @K@_^)KI** .;_X5QX(_Z$WP_P#^"N#_ .)H_P"% M<>"/^A-\/_\ @K@_^)KI** .;_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\ M/_\ @K@_^)KI** .;_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\ @K@_ M^)KI** .;_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)KI** . M;_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)KI** .;_X5QX(_ MZ$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)KI** .;_X5QX(_Z$WP_P#^ M"N#_ .)H_P"%<>"/^A-\/_\ @K@_^)KI** .;_X5QX(_Z$WP_P#^"N#_ .)K MCEC^'Q^*;>#3X"T$#R,K??V?!M:XV^88-OE\'RSNSGVQ7JM>3_\ "K?$?EKJ MW]O)_;@U_P#MC[+E/LGW]NWS/)\[_4?+UQGMWH7Q*^W]?\/\@?PNW]?UM\Q\ MW_"M&\9Z7X>TWP7H-[)>W<]K-.-*C1(7BC+L%)BVRD$;3M;Y2>?2IM/B^%MT MYANO#/AF*X+WFQ(=)$@*6S;9&):!<$<9&.OW2W6ETOP!KND>(-'D>;3WT?1M M3O[]75I&N9DN$?"[ F 59R,!CN&#P1@X.B> _$&H6,&KV$,5K,TVLQ"#5!); ML(KJ4[)=NPMD8!V,%)!ZBIN[:=OQTM^(W:_S_"[O^%C?NF^#MG#:33Z#H/EW M=JE[&Z:"'"0.0%ED*Q'RE).,OM%11'X7'7M?TZ\\&:/9IH?E":ZGT1!'(7 P M%/E\DDJ%'5\_*".:I:I\*==GTO0$TZ33;;5=+TF"P35K>\N+:>V= Q&T%9X MSSA&5#_M<\7M?^&>M:MJ'B!DO+1XM3DL+R*U"C8P1G/3FG^"=!\"^,O"L&MQ^!/#ULDTLR+&+""08CE9,[O+'7;GIWJG M;?#C5;.>SUBSATZ+5;;5_MS6\FI7=PDR&$PD/<2AG+[3D$(!P!CO75?#[P]? M>%O!L&EZM+;2W:3W$LCVN?+/F3/(,9 (X8<=O>ET_KLOUN)_U^/_ !?^%<> M"/\ H3?#_P#X*X/_ (FC_A7'@C_H3?#_ /X*X/\ XFNDHI#"BBB@ HHI'!:- M@IVL1P?0TGH@.>N/'WANUU5-.FU!Q.SN-2M[ MQ3$DD8*RI<1N>+M#OH](>UOA(NL[_ +#B)P9= MBEFX(RN #G=CGCKQ5/P[X>&A/KMM8V$-C87%PLMI# JI'S!&KD*O"Y=3GIDY M/?-1+QVVK"]O(I)Q(1U7H1#(0>X QU&=*"9;BWCFC#A9%#*)$9& ( MSRK $'V(!%>::7X0URV\61WDUCMMUNI9"_G(?E9KX@XW9_Y;Q?\ ?7L<5O#_ M (+U>ROM--WH@2_@,+MJ_GQ'9;K9B)K7(;?_ *P$[<>7SNW;N*7<'N>KU +R M W[66_%P(A+L*D90DC(/0\CG'3(SC(SYGB]ALWMP\ M]S%(S2$B4-'*^",^9\KC@MQQJ^#-.U2QFT'3[ZUALY]/BNI)HH45-D,C 1AD M5Y$0NP+;$,U@?%;7_ !!8V%GHOA>QOO.U4M'< M:K!I\UTEA#T9ML2L2YSA1CU/O7':KX6GTNQU73]!TS5;JQU?PK!I6F/]CEW" M5&D!68%08>'#9<*.O/&*2OO_ %LW^=DANW]>J_2[/4[OQOX>L=<_LBZOREV) M(XG(MY&BB>3[B/*%\M&;L&8$Y'J*DT;QAH7B"]DM=(OOM$J(9!^Z=%E0-M+Q MLRA9%#<;D)&>]>:>+'U?Q1XKL_"-_9ZK8^'-,$+S7<>E7,HU*Y4 HJR)&RI& MK8)8D=#^%KX=Z-JD>K^$X[O3KVR/AW0Y[&^-S T:&9GC"JC'B08C+;E)&,V,>D7,8L+,12HB1AHP9F5I,MLW'G.#UI+5V]/S_KT&](W]?Z_ MK<]AOO'/AK3?"R>([[5H8=*DX2=@V6;.-H3&XL"""N,C!R.#3]6\9Z#H=]'9 MZG?&*9XQ*0L$DBQ1EMH>1E4B-2> SE1UYXKRO7_ T]]\"]4ENM#FNM9:ZN[K M3X&MV>X@2>ZWX"M:?Q*T'4;O5-1CT*'4OM>MZ&-/D"Z:9[>8A MCL43!Q]G8;VRT@*E3QR*'=6_KI>WWZ DFM^_YK7[G<]=ZT5!90M;:?;P2-N> M*)49O4@8S4]4]'9$IMJ["BBBD,**** .7C^(WAF2^^RB\N5/VPV'GOI]PD'V M@-M\OSC&(]VX8^]R:ZBO"E\.>(+6);R\@U6\T3_A+IYKW1%M0"T9GS%N?B9?2S_:H[AM6MIM,O(-&DN7CM@J[E6Z\U(H8\AP M\;#)R3AB11'WE'S_ .!_G]R]0EHY6Z?YO_+\3VJBOGWPMI4][J4,_AK3;B'6 MX?%&HO<:IY#",6H,@*-+C;@L5 CS][+;>]6+7P]K'_"/-%I^B:E:WZ>'-0@\ M0M+;N#?W;1XCPQ_X^'+[B'4M@'&1G%3?W>;RO^%_^!ZCM[W+YV_&W_!]#W"X MU2RM=1M+"XN8X[N]W_9X2?FDV#+$#V'7ZBK5>+R>![32M1^'U[8>&(X)([&6 M.[GATTN\=TT$8B>;:I8$2 G>WW3DDBL31O#'BO\ L&_%BM]:ZW_8-Q;WJII$ MMK]IN"1@R7,DQ%Q-D-MDC4C#'E<@5A.,KS'X8Z7%9>,O$-QINA M7ND:7-8:"#C;D MA]#45X7J7A[Q,OAKP;!XA@ENK2#29HKN&;2YM4\JX. MTQ[H8G5MX3*B0DA2#TSFET#PEJEC9>,M1O\ 0KG6-;ATRTCTZXU&W,4TS"SV MN$97)#_PMY,!VUM_6Z7ZO[B;Z?UV; M_P" >XT5X,WA#5+^33H]4T6[GTY;?6VL[>:!G^S0OM^S1N/X3C[J'!& 5X ML>)=+U;4/!/A#3]4T2^N5&@,)I3IKWLT=WY486,QL"L3$Y_>NA*X(!7)J;Z7 M_KK^.GXE)7=OZZ?AJ>C^)/&"VGAGQ+=>'GM[G4-!C;[1%<*ZI&XC$F#P-WRD M'@XYQD4_6]=U6R\3:!8V'V&2'4'(F@=7:=E R\BD$*B(.K-NR65>"03QOP4T M;4!X?UR'Q3IEVOVPVJR1ZG:LOG@6<2."KCYAD%3]#FO0_P#A%- .HIJ$FC6, MM['*9H[F6!7DC<]2K,"5Z#IBK:Y9+Y?D3>\=//\ X!K4445(PK U;QOX?T2^ MDM-1OF26%%>X,=M+*ELIZ&5T4K$#URY7CFM^O/--NKGP;XI\5?;]'U6_.JWZ MWMC)86;3B=3$B>67'R1E2A'[PJ,UST)6#J&4AE(R"#P12UXE M\4=*U:76_%$MKHVI78U;PY!;6HM;1YLRI.6=&* JI"G/)Y[9-7]1\)->:M\3 MM1N-">>\ETZ./3+B2T+.Q-D480DCJ3\IV\GH:3=HN7D_P=AQ5Y*/?_@?Y_@> MO45\\ZCX&OK(006^E2V4%SH=H+1[30I+N:&] Q*ZLDD8@GSL)EE/(&"WRD5K MZEX7U0^,;_5#I=Y->IXETAX[U+9@3"(D69U(R G4,02.Q/%7;WK>=OQM_P ' MT)OI?RO^%_\ @'M]%>3^']!M&UR\M_%7AS4[SQ!ZUB[U0,9=)V>'8'+9W1VK/EOQWKGW%3'5?*_] M>CLO^&&]/OM_7R3?_#GJM%%% !6/K/BK2-!NX;74)YFNID:1+:UM);F4HIP7 MV1*S!02!N(Q6Q7!WK3^&?BE?Z[>Z?J%YIVHZ9#;Q3V-I)=-!)$[DQE(PS -O M!!QMR.2*75+^MA]&=EINI66L:;!J&EW,=U:7"[HIHFRK#ZU:KP?5=&?3M$\' MIXETR7R;_P 6W%X^F>7YK10RB9A&R+G=PW];M?I<72_I^2_P _P/HF"\CN9[B* M-9@UNX1S) Z*20#\K, ''/521GCJ*GKPZ31+IM5XP+B^&=4N]"\+VFHZ7=2V"^*I9XK26)F-M8$ M2^6L@_A4 @;6P "%('2I6MOE^-O\_P &)Z7^?X7_ ,OQ1[+7*^+O&"Z/I6NQ MZ.]O-K.DZ=]O:WN%<(L9W;6) PV2C?*"#QU%>23Z%JS^!-#T?4O#U^]M%#J: MQDZ7)=R12>>P@C$3 I$"N-LKH< ?*R@DUUGPWT;4)M9#>(M,NFAG\)Z?:W'] MH6K!9)%,HDC;>,$C(R#SSSUIQL_Z\G_E^/H4[1>O]:I?J=AXT\17^@:59WFG M2:>,RJUS'=DEFA!&\QJ&!R (2 M;70$(R[L[2 3@C'6M&D2K]0HHHH&%>2?&"TUS6_'?@;PWH/B;4/#O]J?VAYM MQ92N,^7%'(-RJZ[NA R>-QKUNO+OB,\\?QC^'3V:[KA8=8,2^K_9!@?G2D^5 M-C2N[&'_ ,*-\;_]%H\0?]\S_P#R11_PHWQO_P!%H\0?]\S_ /R171?#C3?" MY\,^&->NWME\0WT67O9)_+N;NY*GS4<[@92#N^1L@;>@QQ0LO'.O2WFGZDU^ MLB:CKUSI+Z.(8\6L<8DPX;&_>/+#-N.,-PHX-.7NMI]/^ OU)3NK_P!;-_H9 MG_"C?&__ $6CQ!_WS/\ _)%'_"C?&_\ T6CQ!_WS/_\ )%.\,>./%D]C;27N MNVT\E]X5N-35[^**"&WN(Y0BL64+A<,-VXD<9X'%58_B#XKL_"^HQ7^HWL.N MVT^FN\5U:VK[(IIE1VCEB'ER1N,X^4,OJW4-*[M_6[7Z?<-Z*_\ 6R?ZEC_A M1OC?_HM'B#_OF?\ ^2*/^%&^-_\ HM'B#_OF?_Y(JW<>-/$=UX@%A::T8(I/ M&3DYZY'%,T;QGXIAN-'N+W5WU*.XU74=,DM6MH MD$BVZRE),H@;S"8QG!VD'A1UJ;Z7\K_@G_[=@'&,''.5H9U=M'\$7L.OWJ7W]D:Q=+=.D4KH5*G:-R$$$C)+!CR>1QB+I) MM[?_ &O,59N7+_6]CH/^%&^-_P#HM'B#_OF?_P"2*/\ A1OC?_HM'B#_ +YG M_P#DBO4_!VJ7&M^!]$U2^*FYO;"">8HN 79 3@=N36U5RBXR:?0E.ZN>)?\ M"C?&_P#T6CQ!_P!\S_\ R17-?#[X=^-_'?@33_$G_"VO$%A]M\W_ $?S)Y=F MR5H_O>>N<[,]!UKZ2KS;]GS_ )(3X>_[>?\ TIEJ1G-_\*-\;_\ 1:/$'_?, M_P#\D4?\*-\;_P#1:/$'_?,__P D5T?C^6[M_$]O=27FK2:=#&N^'1=0\J:U M(CG=I'BW*) 0B,H;?GRF 0Y(;T:WGCN;6*>!_,BE0.C_ -X$9!H6J!Z.QXM_ MPHWQO_T6CQ!_WS/_ /)%'_"C?&__ $6CQ!_WS/\ _)%>VT4 >)?\*-\;_P#1 M:/$'_?,__P D4?\ "C?&_P#T6CQ!_P!\S_\ R17MI&5(!Q[CM7%:/!&X6]F5D)>(;B(=H9@R[8P=PVJ0N0+5V#IZC>"[BTW3=4MK M))8-3>+:)%AP/LP4QS!GF^9G(8 _+RHJXEM.OC>%-,U;4-1U"&Y>756^TR"T M@MV5C'!Y)8QK)S'@* ^!O8X;YA;)_P!=/\QLXW_A1OC?_HM'B#_OF?\ ^2*S M8/A)XWF\57VC?\+A\0+]DLK:[\[,_P _G/.FW;]HXQY&;?\*-\;_\ 1:/$'_?,_P#\D4?\*-\;_P#1:/$'_?,__P D5ZCX MPCNIO#'# TFK? M:X1$UQ#JL_GR1EXE8%9-S%D;EAEB021\N-H%K?R X3_A1OC?_HM'B#_OF?\ M^2*/^%&^-_\ HM'B#_OF?_Y(KVVB@#Q+_A1OC?\ Z+1X@_[YG_\ DBC_ (4; MXW_Z+1X@_P"^9_\ Y(KVVN,^(5E=Q:7-J^GS:PUU;1Y@%I>&*"T*Y8SRQJR^ MTUN?3[O3H;P7+,ADNE$9?9%YQ; =0%5I &W8)5LD/1UL$5S6MU,+_A M1OC?_HM'B#_OF?\ ^2*S=>^$GC?1-.BNO^%P^()_,O;6TVYG7'GW$<.[/V@_ M=\S=COC'&KXNFNDNM2V6NJV=L+V.Z=;*VC=8@\$L&?WDC&0X?8P! MD0F1-I"]9X\_Y%VU_P"PUI7_ *<+>G;2_P#71_J2G<\V_P"%&^-_^BT>(/\ MOF?_ .2*/^%&^-_^BT>(/^^9_P#Y(KVVBD,\2_X4;XW_ .BT>(/^^9__ )(H M_P"%&^-_^BT>(/\ OF?_ .2*]MI'W>6VS&['&?6DW97 \+L_V?O%>G1O'I_Q M=UFU221I76"&5 SL*M,L[E]<^T76G3OJZ:J93']JC>+F$/\H7,CC,/[L@KW K1\06T[>*(X]/U M?4)]RM%*AS-&&\M@V),%U+,6PN-F5JVJ7?_AO^#Z:AW_K^ MO\SC/^%&^-_^BT>(/^^9_P#Y(H_X4;XW_P"BT>(/^^9__DBM34[[Q#H%]J<= MZVI(-0\U?,^VB3<@F8^;;)O/E8C:.( [!YDB9! +5Z1H.JPZQI*W$$-Q;^6[ MP2076#)$\;%&5B"P)!!Y#$'KDTEJK@]'8\C_ .%&^-_^BT>(/^^9_P#Y(H_X M4;XW_P"BT>(/^^9__DBO;:* /$O^%&^-_P#HM'B#_OF?_P"2*S=+^$GC?4M1 MUFU_X7#X@B_LN]6TW9G/FYMX9MV/M''^NVXY^[GO@>_US?A?_D8O&?\ V&H_ M_3?9T >;?\*-\;_]%H\0?]\S_P#R15>3]G[Q7+?PWTOQ=UE[N!62*X:&4R1J MV-P5OM&0#@9 ZXKW6B@#Q+_A1OC?_HM'B#_OF?\ ^2*/^%&^-_\ HM'B#_OF M?_Y(KVVFRB0PN(65)"IV,Z[@#V)&1D>V1]: /%/^%&^-_P#HM'B#_OF?_P"2 M*/\ A1OC?_HM'B#_ +YG_P#DBNNT*'Q'/9^++%_$K-?0:H$^W/:AO*0VT+LL M,>[;'@L=N=^.K!SDG?\ EQ/>?#KP_<7<\L]Q-ID#R32-N=V,8)8D]23SDT^ ME_3\5<#S+_A1OC?_ *+1X@_[YG_^2*/^%&^-_P#HM'B#_OF?_P"2*[C1X+G1 M?B#]@,^K-:7-D[&74[PW"WLRLA+Q#<1#M#,&7;&#N&U2%R.UI=$PZV/$O^%& M^-_^BT>(/^^9_P#Y(H_X4;XW_P"BT>(/^^9__DBO;:* /FWX@_#OQOX$\":A MXD_X6UX@O_L7E?Z/YD\6_?*L?WO/;&-^>AZ5TO\ PHWQO_T6CQ!_WS/_ /)% M=)^T'_R0GQ#_ -NW_I3%7I- 'B7_ HWQO\ ]%H\0?\ ?,__ ,D4?\*-\;_] M%H\0?]\S_P#R17MM% 'B7_"C?&__ $6CQ!_WS/\ _)%'_"C?&_\ T6CQ!_WS M/_\ )%>VUQUS)+JUSXDDN=9ETFRL)XK1I%D,:QPJD(6P-NEJ'>X7]T Q*MA5RQ8DD=@ H8=+_ -;V.&?X$^-98VCD^,VO.C J MRLDQ!!Z@C[14%A^SYXJTJQCL]+^+FL65K%GRX+:&6-$R]:] ;GB7_"C?&__1:/$'_?,_\ \D4? M\*-\;_\ 1:/$'_?,_P#\D5[;10!\VZ)\._&^L^._%'AO_A;7B"'^P/LG^D>9 M.WG^?$9/N^>-NW&.IS[5TO\ PHWQO_T6CQ!_WS/_ /)%=)X)_P"2[?$__N$_ M^DS5Z30!X5<_L_>*[V2WDO/B[K-P]K)YL#2PRL8GP1N4FX^4X)&1SS5C_A1O MC?\ Z+1X@_[YG_\ DBO;:* /$O\ A1OC?_HM'B#_ +YG_P#DBC_A1OC?_HM' MB#_OF?\ ^2*]KE$AA<0LJ2%3L9UW 'L2,C(]LCZUQ?A1=>=/%EG<:X+K48=3 M$<-W<6VZ*+-M V%A#C" L<+NSW)8Y)-[^E_R_P QG$?\*-\;_P#1:/$'_?,_ M_P D4?\ "C?&_P#T6CQ!_P!\S_\ R17H7@">]/@N1M0O;C4[J&^OHS/.07EV M7,JCI@#@ #H !61X/NKN+5O#LCZA=W9U_1I;^]6XN'E43*82&C4DB)?WS M#:F%Z<<4[7=OZV;_ $8OZ^XY3_A1OC?_ *+1X@_[YG_^2*/^%&^-_P#HM'B# M_OF?_P"2*]MHI >)?\*-\;_]%H\0?]\S_P#R17-?$'X=^-_ G@34/$G_ MK MQ!?_ &+RO]'\R>+?OE6/[WGMC&_/0]*^DJ\V_:#_ .2$^(?^W;_TIBH ])HH MHH *\M^(UU-9?&?X:7%M87&H2I_:NVVMFC61\VZ#@R,J\9SRPX'<\5ZE7FWC M@X^.GPQ/MJW_ *3+2;LK@:EO.EIJTVJ6GPMU1\^;>1+IBS29Z[G%SD_B: M>EZT>JRZG'\,=474)DV2W:C31*Z_W2_VG)'L37-^'_B)XFN=.\*ZIJQTB>V\ M132P"TM+62*:W*JY#AFE<.H\OYOE7&16EX'^*:^(=(M?[8TN\M]2DTM]2Q;V MVZ.YC5]C>2H=G)!P-K $YXR.:=MUV_K\AV_K^O,T;>[^QF(VGPOU. PP&VC, M0TQ=D1.3&,7/"D\[>F:KVR6EGIMSI]I\)KR"RN_^/BVBBTM8YO\ ?47.&_&F M#XP:"NDZW>36>H))HA@%U:J8)9<3,%3;Y3R"P8=QTJ34?BK9:3=7EMJ/ MA[7()["Q74+M-ENWD0%V7<2LQ!QMS@$G!Z$Y 'IO_77_ ((:CK=X;18EM?A5 M?P"&;[1$(X],79+MV[QBYX;:,9'..*ECO#"T+1?##4XV@F>XB*C31Y.)"T4JLR2[VD"(A"'F1D(. 1D@4 MMI\4='U/2M*N]&LM0U.?55F:WL;58C,%A.V1F+.$ !P,[SG(VYIZK^OZ_P" M+2Q' 8+5KUK;X4WT+:@I6\,<>F*;D'.1)BY^<')SG/4U2;9GTXQF/&-FW[3C;CC'3%1ZC\2])TU"\ECJDBP6:7U\!:[&T^%R0&F1R MK \-\JAFPI.,(P0RAM-#1QG&44_:!P..!5$0V M06]4?"2[ U#_ (_ (=+_ -)YW?O/](^?GGG/-5-*^)]SJ&HI!?:;)I:-X@FT ME3)&DPD$<;L6&[I/CZTUBW:[M=&UK[ UL]S:WGV/?'=H MI_@"%F#'^%7"ENP-&ZO_ %JKAL^7^M'8H6GV>P\O[#\*+ZV\J431^3'I:;'" M[ XQ<\,%^7/7''2B#[/:R-);?"B^A=S(6:./2U+&0 2$D7/\0 #>N!FL[4/B M[!-IEZ=$M##J-A?6-O?_ W7M1LO@QH5O;>$]8U")/M&VYMI M;-8WS<2'@23JW&<R5YM^SY_R0GP]_P!O/_I3+0!/KUHGB2^M[O5/ MA[XF:6 ;3Y-_9Q"=,,/+E"W8$B?.WRMD?,PZ,P.ZOB;544*O@/7U4# GT_ M'_@572T4>0;G-_\ "4:O_P!")X@_[_Z?_P#)5'_"4:O_ -")X@_[_P"G_P#R M57244 01_X%5ST5@;.UN4TWP)XKMII;9[>&9M4M MI3:*PZ0AKT^4.%XCVCY5]!CI=3\6+I_B[2M"33+R4W\K1O>&,QP0_NGD #$? MO&/ED87..Y' )H?BQ=<\2ZII<>F7EI'I\4,BSW<9B-QO:125C8!@H,1P6QGJ M!C!(NZ&]/Z[F+.6N=9CU2?X?>)6N4V$C^T+012,GW6>(7GENP[,RDC P>!BI MI^G1:5>O&,QP0_NGD #$?O&/ED87..Y' +1XBU*#Q-:Z?J>C1VMG?RRPV"\L][8RRRD*%!9VNR3@ =@ *[F MBC8#F_\ A*-7_P"A$\0?]_\ 3_\ Y*H_X2C5_P#H1/$'_?\ T_\ ^2JZ2B@# MF_\ A*-7_P"A$\0?]_\ 3_\ Y*K&U6,:S>_:K_X>^)C(R".40ZE:PI.@SA)4 M2\"RKR?E<,,,1T)K=\9^*E\(>';C4O[-O-2DCC=U@MHSCY5W$O)C;&H ZMUZ M ,< UM?\83Z/<7'V73%N[?3[);_4I&N/+:&%BV/+78WF/B-R5)08 YYX!ZF3 M=BYU#SUO_ _BF16N!/!Y6HVD+VI$:QXB=+P,@(!R%(!W'CDYG\UO^$=FT,_# MKQ =/N(WCFC-Y9%I0^=Y9_M>YF;))8G<2V_L73AJ-S=2;(P M\IBA0;2Q>20*Q5<# ^4DL5&."]<@ U;36#R36)!(OH"%^6Y)RQ 4=LD M9(&2-^_\9P66H:!8K:O-<:PZ!E5^+9&1F#,<=RI '&<,?X32^//^1=M?^PUI M7_IPMZK5:=G^)*M^'X!_PE&K_P#0B>(/^_\ I_\ \E4?\)1J_P#T(GB#_O\ MZ?\ _)5=)12&(/^_P#I_P#\E4?\)1J__0B>(/\ O_I__P E M5TE(QVJ2>@&>!2=K:@>?Z?:QZ6MP+#X>^*(?M$1AR-4MB88R<[(2;W,*Y[1[ M0,#T&(SIZ#6KC58_ GC&"[NI5FG,&NQ1)*Z@ %HUO@AX4#!&,"MKPWXRGUS4 M;6"ZTV&UAU&Q.H6$D5YYS/"&4'S5VKY;?.G +C[PW?+R[6?$/B#2M;LK2'1- M-NK>^NUM[=AJDBSLN-SN8_LY4!5#,?G[ 9R0*JSNOZZ_Y@^MRG?7_ M#SQ!*UU;_9I2;NQ!\O).%Q=_(IW>BZ>MEIWP_\11PJS-\] MW8R,S,2S,SM=EF8DDDDDDFNPHI (/\ O_I__P E5S_ASQ'JD>O>+&3P M7KDIDU:-F1)K',1^PVHVMFY S@!OER,,.1PQ M5%+$(A8D#T Y)]AS0!R-MJEW:37TMO\ #[Q CW\OG7)^TV)\Q]BIGF[X^5%' M&.E,LKZYTZTM+6S\ >(X[:SMOLL,/VVR*"/ &"IN\,<*!N;)'//)RVT^($^I MQ7":?H4T=[_:@TZTM]0E-OYO[@3^9)A6:(;"QQM+?=! )('1>']977='6\\D MV\JRR03PEMWERQN4=<\9&Y3@X&1@X'2G9V^[\M/P?Z!M_7]=CE=)C&B77VC3 M_A[XF$BH8XO/U*UG6!#C*1+)>,(EX'RH%'RJ.PQL_P#"4:O_ -")X@_[_P"G M_P#R53]#\6+KGB75-+CTR\M(]/BAD6>[C,1N-[2*2L; ,%!B."V,]0,8)Z&D M&SL(/^_^G_\ R57-?M!_\D)\0_\ ;M_Z4Q5Z30!S?_"4:O\ ]")X@_[_ .G_ M /R51_PE&K_]")X@_P"_^G__ "57244 (/^_P#I_P#\E5SN MIV,X.,@&I9]2U/[3>WUAX%UZVU.[MEMS=--82! M0F\I\GVL X,C'MG/)K;\*>(&\3Z NI/82Z>QN)X3;3.&=#'*T?S%>,_)D@$@ M9QD]:J1>+OMWB75M&TJQ-S+IUH)EE>78D\NYE,0.#T*X+(O)M8EB0O<:>6( QDG[5R3U)]:M_\)1J__0B>(/\ MO_I__P E5LZ7J,&KZ3:ZC:;O)NHEE0.,, 1G!'8CH1ZU;IN]]1+8YO\ X2C5 M_P#H1/$'_?\ T_\ ^2J/^$HU?_H1/$'_ '_T_P#^2JZ2BD,\;\(:]J,7QG^( MMQ'X3UB>6?\ LSS+:.6S$EOBW8#>6G"G=U&UFXZX/%>@?\)1J_\ T(GB#_O_ M *?_ /)5(/^_\ I_\ \E4? M\)1J_P#T(GB#_O\ Z?\ _)5=)10!S?\ PE&K_P#0B>(/^_\ I_\ \E55M-6O M+&XO)[7X?^((Y+Z83W#?:; [W"*F>;OCY448&!Q762R"&%Y'#%44L0B%B0/0 M#DGV'-/OMNCZO>IHUU!)97\=A;VUT?*DN'D6+RV88S$"9ER""RJ,D9RH M%OI_6O\ G88RTOKFPBCBL_ 'B2&..XEN0B7UF TDA9G+#[7\P)=CM.0#@@# MQ7T@#0KN:YTSX=>(HI)05^:^LY%B4MN*1JUX1&N3G:@4=..!71Z#KLFJ17T5 M_:+:7^FSF"Z@AE,R!MBR*4;:I8%74_=!SD8XJCI/B?4KK6;2RUC1%TY-1MY+ MFSQ=^9*%0KE9HRB^6V'7A2X!R">F3J+?<=_PE&K_ /0B>(/^_P#I_P#\E4?\ M)1J__0B>(/\ O_I__P E5TE% '-_\)1J_P#T(GB#_O\ Z?\ _)5>?_'+7M1O M?@QKMO<^$]8T^)_L^ZYN9;-HTQ<1GD1SLW.,<*>3V'->R5YM^T'_ ,D)\0_] MNW_I3%0!Z31110 5YMXW&?CI\,1_V%O_ $F6O2:\C^+.@:5XG^*WPYTCQ#;B MYTZX&J&>(R-&"%@1Q\RD$8*@]>U)V:U ZWP5\-]&\&Z%;VT%I8S:G'$\4FJI M8I%-*&8GDC+=P/O'I6%%\'571H-/DUV3;%X?FT0R1VVUF\R0/YOWCC&,;>^> MHK,'PG^!YT4ZP+?2_P"S _EF]_MR7R0V<;?,\[;G/;-:J?L__"Z2-7C\-AT8 M JRZAH_>4WK>_P#6C_1L:=OZ_KL0GX07,]EK4-WK]J&U6"RAQ:Z4(8X! M;2;EVIYIX8<$9ZY/H!M>(OAU_;^J^(;W^U/L_P#;6BC2MGV?=Y.&8^9G<-WW M_N\=.M8EQ\#/A)9SP0W>B002W!80QRZI<*TI4;FV@R\X )..@YIUI\"/A/J% MG%=V&@Q75M,H>*:'4[AT=3T(82X(^E#][?S_ !T8E[NWE^%K?D3:S\)9-1\5 M6VOVVM0QW%JEJL4%S8>?"3"DB;G7S%W9\S(Y&TCO3]'^%MWX?MM*FTK7XO[6 MTUKM4N[C3]\"""".U#?7U_'<+:6]/PV+>L_"<: MSJB:E=:E8WM]+9QVEY9@CYP00H(Q@YSD.A^&^I)X/G\*2>*'&B"P MEL;:*&Q5)55N%:60L=^T<841YRI) [DU/_P ,^?#'_H6?_)^Y_P#CE396MT_X%OR'=\W-U_X-_P R%/A! M>#D^@'I]>;?\ #/GPQ_Z%G_R? MN?\ XY1_PSY\,?\ H6?_ "?N?_CE5=LFR/2:*\V_X9\^&/\ T+/_ )/W/_QR MC_AGSX8_]"S_ .3]S_\ '*0STFO-OV?/^2$^'O\ MY_]*9:/^&?/AC_T+/\ MY/W/_P _T5YM_PSY\,?^A9_P#)^Y_^.4?\,^?#'_H6?_)^Y_\ CE 'I-%>;?\ #/GP MQ_Z%G_R?N?\ XY1_PSY\,?\ H6?_ "?N?_CE '8:WH]QJ6L:!=P/&L>FWKW$ MP%P.3F0=<<9JM/I]_IWB+7/$%M#%=^=ID$5O:B1E>22(S,5)"G / MF* 1D]>/7F/^&?/AC_T+/_D_<_\ QRC_ (9\^&/_ $+/_D_<_P#QR@=_Z^=S MK]9TBXU/5O#]W"T:)IMZUQ,KLUC4?%5O?7EOI- MF;61MNK6,CB[G@PX6!D*85 MR45YM_PSY\,?^A9_\G[G_P".4?\ #/GPQ_Z%G_R?N?\ XY0!Z317FW_#/GPQ M_P"A9_\ )^Y_^.4?\,^?#'_H6?\ R?N?_CE '9>+-)GU[P=J^DV;QI/>VV\I2?+D6)S&Q8[ MZUX9CMX[C_A'KNVLKBTM[/39X[BUQ(,99I;?=DXP64!L%N3DFJ/_ SY\,?^ MA9_\G[G_ ..4?\,^?#'_ *%G_P G[G_XY2:NFGU!.UK="7_A6FI13Z5<0^+- M3EE@O8;FZ$ZVN"(XBF$(M\\9P 3C!8_>.:Z#QY_R+MK_ -AK2O\ TX6]+?@;\.M,T6WGL?#WE2OJ>GP,WVVX;*2WD,;CF3NC ML,]1G(P:J]_S_K[B4K'LE%>;?\,^?#'_ *%G_P G[G_XY1_PSY\,?^A9_P#) M^Y_^.4AGI--D4O$Z*Q0LI 8=5]Z\X_X9\^&/_0L_^3]S_P#'*/\ AGSX8_\ M0L_^3]S_ /'*35U8-BUX6\'ZWX?U#[6;?2HY8+*2"1[:ZD#:S.2I6XN28_E8 M;3S^];]ZWS?WNG.D3R^-$U>X,9@M[ V]NH8ED=WW2G&,8(2( Y['@=^._P"& M?/AC_P!"S_Y/W/\ \;?\,^?#'_ M *%G_P G[G_XY1_PSY\,?^A9_P#)^Y_^.4 >DUS?A?\ Y&+QG_V&H_\ TWV= MZUXF@N?#V^*QU-(+=?MMP-B&SMI". M).?GDDT5YM_P ,^?#'_H6?_)^Y_P#CE'_#/GPQ_P"A9_\ )^Y_^.4 :ESX3U:' M5;W5].-C+=C65U&UAGD=$DC-HMNZ.X0E#]Y@0K=%]3C8\,Z3>Z)IZ6UR+>5I MY;B[NY4D;Y)I93)L12OS*-[#<2#\H^7DXY/_ (9\^&/_ $+/_D_<_P#QRC_A MGSX8_P#0L_\ D_<__'*.E@>O]?UW9V%KH]Q!XVU/6'>,V]W96UNB@G>&C>9F M)&,8Q(N.>QK9KS;_ (9\^&/_ $+/_D_<_P#QRC_AGSX8_P#0L_\ D_<__'* MW=STFBO-O^&?/AC_ -"S_P"3]S_\;?\,^?#'_ *%G_P G[G_XY1_P MSY\,?^A9_P#)^Y_^.4 >DU@Z-:S:?XEUV*6*0Q7TZ7T,VTE#F)(V0GH&!CSC MT88Z&N4_X9\^&/\ T+/_ )/W/_QRC_AGSX8_]"S_ .3]S_\ '*.MPZ'4Z!HV MH:-HQL',#&:^O)I)8YB#%'+++(A4%#N8;E!!P!RI M:GIUMI8MTMI(H7FD*N[8Q'"I;[V0<[BQ.DT5YM_P ,^?#'_H6?_)^Y_P#CE'_#/GPQ_P"A9_\ )^Y_^.4 '@G_ )+M M\3_^X3_Z3-7I-> >%O@[X$U'XL>.]&O="\S3])_L_P"Q0_;)QY7FP,\GS!\M MEAGDG';%=M_PSY\,?^A9_P#)^Y_^.4 >DT5YM_PSY\,?^A9_\G[G_P".4?\ M#/GPQ_Z%G_R?N?\ XY0!Z37'W?A*_F@\0-#-:BXO-5@U*QWEBH:%(-JR<<9: M$@D9P&SR>*QO^&?/AC_T+/\ Y/W/_P L:<^H7US#8M?:K=FXN(DN7,=NJPK&BHWE@R?ZM3N))K&_X9\^&/_0L_ M^3]S_P#'*/\ AGSX8_\ 0L_^3]S_ /'*.OX!T/2:*\V_X9\^&/\ T+/_ )/W M/_QRC_AGSX8_]"S_ .3]S_\ '* /2:\V_:#_ .2$^(?^W;_TIBH_X9\^&/\ MT+/_ )/W/_QRN)^,7P=\">%?A/K.LZ#H7V74+;R/*F^V3OMW3QH?E9R#\K$< MCO0![_1110 5Y=\1_P#DL7PZ_P"N.L_^D@KU&O)/BO?:IIWQ8^'%UH.D?VSJ M$?\ :GE6/VE;?S,6UE='X<_\([Y;?V9 M-I#^)F/;+0:M!874-[9)IUO/J,Z&:U,:%@ MMG'$RS*W[P&4G*$=5"UUW_";?$[_ *)'_P"7+;?_ !-'_";?$[_HD?\ YGJ9\ONV_K^KW?\ PQQ=MJ4EYX\T&34M4NY-=BUC5UN; M-YV9;5%@E$.U"<1#8%*[<;\D\XXT=.URYG\,_#\^*M>O;#0[S299;W4O[0DM MVDN0J>6))P0PX+D L-Q'.<8KH_\ A-OB=_T2/_RY;;_XFC_A-OB=_P!$C_\ M+EMO_B:A*RMZ?@FOUO\ (IZN_K^+O_P#@K_QI.?$UC)I7B34E%MJ]A:HNIW, MR3WELX0-*;8+'&L3;OONC%B>"N5%>D?"[_D2M7_[#.I?^E#U4_X3;XG?]$C_ M /+EMO\ XFC_ (3;XG?]$C_\N6V_^)IO6+7>_P"-O\OQ'U3[6_"_^?X'%^&] M1M]5\&_#>T\,W5M>Z_I<[S2PP2"22VB$,H<2 '*!B47YL9)'6F^';SQ9XGTV MYMK/Q%Y>J3Z+-)>00ZK<3W$5XK HS)Y2I:-N#(8@P!!. <9KMO\ A-OB=_T2 M/_RY;;_XFC_A-OB=_P!$C_\ +EMO_B:'JV^]_P 5;^O,.WE;\[G.#Q%K6K?# M*7Q?]NOK-M8UNP%M"L[J((%FBB9%&> S"0G'W@>MK'B#4H?%B MZG>10:-'<.T;PKN\D&WP5$6T*WFX7)ZOSBM#_A-OB=_T2/\ \N6V_P#B:/\ MA-OB=_T2/_RY;;_XFAZWM_6R_3\25I;^N_\ G^!YU;>(/%%_X?FDC\70Z?=O MIA;5 U]>7;V\_FI\TB)!BQ_C0JK# )8?=W5Z?\(M8GU7P]J"W#7$QM;YXQ.V MHF_@D^53^XG8;GCSGABQ!R-W&!5_X3;XG?\ 1(__ "Y;;_XFC_A-OB=_T2/_ M ,N6V_\ B::=OZ\[C?\ 7W6/2:*\V_X3;XG?]$C_ /+EMO\ XFC_ (3;XG?] M$C_\N6V_^)I >DUYM^SY_P D)\/?]O/_ *4RT?\ ";?$[_HD?_ERVW_Q-<;\ M)O$/C[0_ACIFF:-\.X];L[9[A$OXO$%M&DQ^T2;MHYX#9 ()!QD'!% 'O=%> M;?\ ";?$[_HD?_ERVW_Q-'_";?$[_HD?_ERVW_Q- 'I-%>;?\)M\3O\ HD?_ M )A'PU MJ6F"ZM_#EY=:I922G4M(L/+E."C,7G+,9E8N#NPG(''/"?\ ";?$[_HD?_ER MVW_Q-8WVCQN>M"T=PZ6+?B> MT>'Q9>7T6FQ7.HC5[!;36([F,O91L85:VV[O,0L#(=@78RREB>M:MYIVFZ?X MXT?6-)@LH8+RZG@N-4M;@275U,R2YBD+#F-2F?OL5,:J$55)&2VL^.&U>+5G M^!]FVI0Q^7'>MKUF9D3D;1)LW U&RM_71?I_P_5WOO\ U_7]6-WP=HNF-X@BU;PO:"#3(;9X M)=2( DUJ0E?WK$8\P*58^8W+%B5^7EMJQ_Y*GKO_ &!=-_\ 1]]7!:7/XIT2 M\^UZ+\ =*T^YVE/.M-8L8GVGJ-RH#BF6GB_XBKX^U6=/A=ONWTRR26U_X2"W M'E(LMT4??MP=Q9Q@;?\)M\3O^B1_P#ERVW_ ,31_P )M\3O^B1_^7+; M?_$T >DUYEX]M9KKQ!JEW=0:==6>C:3%?107D+O(2'F+F!E=3#(=B#S1DC"\ M>LG_ FWQ._Z)'_Y?6K)XXCZJI3 _"E;7^OZT$M$4%4330;6.]:_P!-6QO[6>+_ (ET M1\E#:*F?,0,I=@BKL9)=Q/6O2/'G_(NVO_8:TK_TX6]<6=9\<-J\6JM\#K(Z MC#'Y4=X==L_.1,$;0^S,]S5/Q;XO^(MQHMNE]\+OL<0U/3W63_A(+>3< MZWD+(F O\;A4ST&[)X%5?2W]=/Z_JX=3V2BO-O\ A-OB=_T2/_RY;;_XFC_A M-OB=_P!$C_\ +EMO_B:0'I---(L[C=]FAM+F_"@9W2QF)%..^T2L< M>I4]0*YO_A-OB=_T2/\ \N6V_P#B:IWOB/XD7MW9W3_"62.>SD+Q21^)K4'! M&&4Y4Y4CJ/8'@@&DU?\ K^MMQB?#F)+7Q!H\RVEM:?VIHDEP)K5MTFI@/$?/ MNA_#*-_ S)S))^\X .MK.BZ9K/C"2+2K87>N1W4$]SJT@!.DQKL(A1Q@@NJG M]VI_Y:,S\, V%!?^,+7[=]F^ ^FP_P!H B\\O6K)?M.5:=XC^)&F_:FB^$KR2W< M[7$TLGB:U+.QP!T4@'I-%>;?\)M\ M3O\ HD?_ )Q*L0#V)KE MO^$V^)W_ $2/_P N6V_^)JKJ7B;XCZKIL]C>?"$F&=-K;?$UL&7T(.W@@X(/ M8@4#0NH6;V_B^]U>YL].GATO5K*TM8O(;[7%%(D"*(95=?*0-(S%-K!_F!P* MVO'FGV]_K&EC4M)M]=LEM[G=ITL\2[6_=XN-DK*K*@W L,LGF @')KGCK/CN M34K;4[GX*6MSJ=K'Y46H3:[9&=5P02 M[U+2#%>LQ),P6-71V)Y)!+ $_P#/0YY-=_7E7_"1?$@ZV-4?X2N\Z6_V>)6\ M36NV)2VYMHV]6(7.2?N+TYS<_P"$V^)W_1(__+EMO_B:J3N[DI6/2:*\V_X3 M;XG?]$C_ /+EMO\ XFC_ (3;XG?]$C_\N6V_^)I##]H/_DA/B'_MV_\ 2F*O M2:\ ^,7BGQWJ/PGUFUU[X=?V-I\GD>;??VY!<>5B>,C]VHRV6 7CIG/:NV_X M3;XG?]$C_P#+EMO_ (F@#TFBO-O^$V^)W_1(_P#RY;;_ .)H_P"$V^)W_1(_ M_+EMO_B: /2:Y6PMY-8UOQ0S7<]G;(T<.HZ@GF32L[D"[E&6( M_'\?E>7\%;9?)E>>+;X@M!YV2.3N/J:IPW_C>QCOO['^"=MI, M]^I$]U8:[912L3GYBPCY8$D@G/)H>]_ZV'W]?UN>B>#KJ>\\'Z=+=RM/*(S& MTS=9=K%0Y]R%S^-;=>867BKXCZ=8065E\'EBM[>-8HHU\2VV%51@#[OH*F_X M3;XG?]$C_P#+EMO_ (FF]R5L>DT5YM_PFWQ._P"B1_\ ERVW_P 31_PFWQ._ MZ)'_ .7+;?\ Q-(8>"?^2[?$_P#[A/\ Z3-7I->">&_$/CZR^*GC6^M?AW'= MWVH)I[W5@GB"V!L0L3HFY^02X4MC (&.,,">R_X3;XG?]$C_ /+EMO\ XF@# MTFBO-O\ A-OB=_T2/_RY;;_XFC_A-OB=_P!$C_\ +EMO_B: .R\6ZA<:5X-U MB_LCBXMK*66-L9VL$)!_#K^%>??$.]CTK1[30H(-4@TZP^R3F:WL+B5+I_/3 M"&5$*\8+,"0;DWC#XE7$$D,_P?62*12CHWB2V(8$8(/RU4MM?^(L.C MPZ9/\(C>V\*JJB[\26DA(4Y7/R> >O-+_@!_P?T.D\>^7J%OH%F+.& M_P#MM^-NGWX,=O=8AD;9-D$J!C< 4<[D4;?XER?!#+:7&A?925,S:A87,*_< M589F**AR/E;D+]T4+G6?&][ILFG7GP.LKBQD_T444 %>7_$ M-KA/C-\.&LMGVD1:P8O,4E=_V5<9 ()&?<5ZA7FWC;_DNWPP_P"XM_Z3+2:N MK(:T=S%MOC-J=Y?>#UM[&TDM=0MX)-;F5&/V5YI?)14^;Y?W@;[V[@5KZ)\7 MX+FSU"YU&RGN(K::XG:33X/EM+%)6C267>^26V.<("<#.W%1VOP2L;7P]XMT MU=5(;@RPW'D6YWOR=X^;ID9IW_ *]=;?*UO.XFE?\ KI_G>_R+7CGXG+X< MM;^WT33+G4M0AT8ZM%*J(;9(LE0SDR*Q&1R%R2#QGG$7C/XGOX>\.WC:98/> M:K:Z9%?S-Y6ZWMA(P5!)\X;YCNP%SC&3@.G6J_B7X73ZVE^FGZ\-/74]+ATZ]W6?FEQ$24=#O7;U M((YR#Q@\T]+_ -?WO_M06ZO_ %\-_P#VXM:M\6?#^A>TYSUX/%5Y_BOI,/B&YMY#/!8V$=Z;B62U#"4VWE[S&XES@%] MN"A).>5QRSQ)\(K'Q+XON=:NK]DCN-*>Q:U$.0)F1D%QG=C<$;:!C\:JQ_!B MT.B:=IESJ\DL=KI5Y83R"'#W#W#*[39+'!#+G!SG/6IU_/\ +_-?CY ME?R_ M/7\_P\RS8_%+.L:\NLZ=/I]G80V)MK:2$&ZEEN=P5#M=D))"XP0!D[B,''6> M'O$EKXBCO!#!<6EU83FWN[2Z"B2"3:& .UF4@JP(*L0<]:XZZ^$TVK0:N=?U MV*^N-1CLE0KIX2*)K4L5)C+MO5MWS*2,Y;!&1CI_!_A2/PK8W,0&G"2ZF\UQ MINF1V,*C 547).,=69CR>0, 5I=_P!=O^#^'S6NGR_+7\3HJ***0PHHHH * M*** "O-OV?/^2$^'O^WG_P!*9:])KS;]GS_DA/A[_MY_]*9: -W7?&%_I_BF M'1-'T:+49C$DLOFWP@8AA(0(UV-N.(7'S%%R5&>21U@Y'3'M7!_$#PGK'B:\ MM([6VTN_LCD WQV/I\ACD7SHR$);[Z' *D-&N",DKV]M$UO:0PO*TS1HJ&1_ MO.0,9/N>M"V![Z$M%%% '+ZQXKU'2;R:9M$4Z/;7,5M-=RW1BE9I"HW11%,2 M(#(H)+J20P .!D\/^+YM7U"UAO=-6RBU*T:^TV1;@R-+"I4'S%V+Y;XD0[07 M')YXJE?Z/XGOO&+7=]8Z3J&DP.HL(9-2EA\@$8>5HA P>7DX)? & -I+$Q:5 MX>UW14MKN\BL[L^'M+FLM-BMIGW7H.S#2 I^[;;"@VKO&6)SP!1'S_K3_.WW M_[C,1N-[2*2L; ,%!B."V,]0,8)98_\ M)4]=_P"P+IO_ */OJMVNCW$'C;4]8=XS;W=E;6Z*"=X:-YF8D8QC$BXY[&JE MC_R5/7?^P+IO_H^^I ]W;^M"_P")=;/A_0WOEMQ<2>;%#'&THB4O)(L:[G(. MU=S#)P2!T!Z4WPSJM_K.BQ7NJ::FGR2A71(KGST=&4,&#;5/?!!4<@XR,$S: M[:WUYH\T.EO MP2I"7*AHIE!&Z)^#A77*D@$C.<'&#@?#CPO>>&-#DCOK>UL M&N#&PT^RD+PVY6-48@X4;F(+-@ 9/M_Z_K^EU!]#L**** ,?6M3U:UN M8+70M(COYY$>1WN;EK>"-5P,&01O\Y+<+MZ!B2,XN]7@>_EM3/)+*9/*6187/E L0>%+ #. 6 M4C\A+97_ *[_ *6-&T^(<-]?^';>UTB^V:T,M<2)LAM\PO(%#])6/ED?(2 . M21P#=\>?\B[:_P#8:TK_ -.%O3[O1;V_G\,7#0V=F=+NC/<6\,K.BJ;>6(+& M=BYP77J%X!^E,\>?\B[:_P#8:TK_ -.%O3=@[>G^9TE%%%( H)PI(&?8=Z*1 MMQ4[" V."1D _2@#GM)\1:E<>(!I6MZ/%ITLUJUW;"*\^T-L5PK+* BA'^=> M%9U/S88XY35?$6I:3J\"SZ-&-)ENHK3[6;S]\SR$!62$(04#, 275AACMP 3 M1L-#UV/Q#+K=QIVB6EZML\!^](WD \'<_7M!UC6 MM8@WV>CK#;SI+:ZL)'6\LU!4NB)L(.[:5+"1 5;E3C#-;K\?O_R_KH#Z_P!= M/\R!/B&?.OHY=,564,-.1+K<]VPG: (RE1Y;&0#'WA@DDC!%=HA8QJ9 %? W M!3D ^QXS7&>)/ <>KW-]-8VFG6IE@9AMC"&[N6!4M.P7)'EEDS\QQ-)QP,[' MA#1I]!\.I97*6\+>=+*MO:,6AME>1F6)"0,JH( ^51QP!TI+;7^OZ_JP/?3^ MOZ_JYN4444 %T?25MWN;C4K@1MM; MT*L0[?4J0!WPW]TT>(O$ M-YI=Y;6.DZ?;WMY/!-7OB.VU7 M3_$5_#_Q,H[RX@<6Y152-D C)A+=_NEL?,QZG-2>*_#>J:_<65R^FZ/J<=NL M\;:7J-R_V3SR2?VH4445(SS;]H/_ )(3XA_[=O\ TIBK MTFO-OV@_^2$^(?\ MV_]*8J])H **** "L>7Q%'%>ZG&+6>:WTR-//DMXVED M,K ,(UC12S$*58X_O+[XV*P=&M9M/\2Z[%+%(8KZ=+Z&;:2AS$D;(3T# QYQ MZ,,=#1U_K^O/Y 2^%/$#>)O#ZZG)8R:>QGGA:VF<,Z>7*T?S%>,_)D@$@9QD M]:P_"WCRX\60W4VF0Z%<+% TL=O:ZYYUQNS\BRQB$"+=@\[FP>,&M7P]I&H: M)I!LG6UF,M_=SR/YC82.6:21,#;\Q^905RHZ\G S0L=.U6RGMK[5M.TZTM]% MM)8[>#16DE-P&"Y B,:^6,(,("_) S\N2/=L?6WG^ITFEZC!J^DVNHVF[R;J M)94#C# $9P1V(Z$>M6ZR/"NGW&E^%[&UO0JW*QEYD4Y".Q+,H/< L1GVK7IO M;>"?\ DNWQ/_[A/_I,U>DUYMX)_P"2[?$__N$_^DS5Z30 4444 M %7-Y'IEAH\EOJ-G]DGNIY'BN(5^8'HCB91O)"DI@YY^;(6MT-6ZEKQ3XEB\ M,Z;#/+]E$MQ+Y,7VNZ^SP*=K.3)*5.Q0J-SM/.!CFKFA:D^KZ':W\D4433IN MVP7"SQD9X9)%X=2.0< X(R >!EZGHNH7.G:5+;VUE+J&CW7G6\5S<-Y1>.C7$UQ-=2K&Q9(VED:0HI(!*J6P"0, MXS@9Q5::DZV1KT444AA7FW[0?_)"?$/_ &[?^E,5>DUYM^T'_P D)\0_]NW_ M *4Q4 >DT444 %DT444 ?_V0$! end GRAPHIC 10 q1chart1.jpg begin 644 q1chart1.jpg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end GRAPHIC 11 regionalsales005.jpg begin 644 regionalsales005.jpg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end XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 7 95 1 false 6 0 false 0 false false R1.htm 0001000 - Document - Cover Sheet http://www.jnj.com/role/Cover Cover Cover 1 false false All Reports Book All Reports a2020q1cover.htm a2020q1exhibit991.htm a2020q1exhibit992.htm jnj-20200413.xsd jnj-20200413_cal.xml jnj-20200413_def.xml jnj-20200413_lab.xml jnj-20200413_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a2020q1cover.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 7, "dts": { "calculationLink": { "local": [ "jnj-20200413_cal.xml" ] }, "definitionLink": { "local": [ "jnj-20200413_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "a2020q1cover.htm" ] }, "labelLink": { "local": [ "jnj-20200413_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "jnj-20200413_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "jnj-20200413.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 33, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 5, "memberStandard": 1, "nsprefix": "jnj", "nsuri": "http://www.jnj.com/20200413", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a2020q1cover.htm", "contextRef": "D2020Q1PressRelease", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover", "role": "http://www.jnj.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a2020q1cover.htm", "contextRef": "D2020Q1PressRelease", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 6, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "booleanItemType" }, "jnj_A0.250NotesDue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "0.250% Notes Due 2022 [Member]", "label": "0.250% Notes Due 2022 [Member]", "terseLabel": "0.250% Notes Due January 2022" } } }, "localname": "A0.250NotesDue2022Member", "nsuri": "http://www.jnj.com/20200413", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "domainItemType" }, "jnj_A0.650NotesDue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "0.650% Notes Due 2024 [Member]", "label": "0.650% Notes Due 2024 [Member]", "terseLabel": "0.650% Notes Due May 2024" } } }, "localname": "A0.650NotesDue2024Member", "nsuri": "http://www.jnj.com/20200413", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "domainItemType" }, "jnj_A1.150NotesDue2028Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.150% Notes Due 2028 [Member]", "label": "1.150% Notes Due 2028 [Member]", "terseLabel": "1.150% Notes Due November 2028" } } }, "localname": "A1.150NotesDue2028Member", "nsuri": "http://www.jnj.com/20200413", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "domainItemType" }, "jnj_A1.650NotesDue2035Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.650% Notes Due 2035 [Member]", "label": "1.650% Notes Due 2035 [Member]", "terseLabel": "1.650% Notes Due May 2035" } } }, "localname": "A1.650NotesDue2035Member", "nsuri": "http://www.jnj.com/20200413", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "domainItemType" }, "jnj_A5.50NotesDue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "5.50% Notes Due 2024 [Member]", "label": "5.50% Notes Due 2024 [Member]", "terseLabel": "5.50% Notes Due November 2024" } } }, "localname": "A5.50NotesDue2024Member", "nsuri": "http://www.jnj.com/20200413", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock, Par Value $1.00" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.jnj.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 18 0000200406-20-000026-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000200406-20-000026-xbrl.zip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

+J;XK-#F K;+OY18']F5T3.?UTN%?_4X11]EW+.]W]8F)=( MZKMX,#B%=V-@B0:*;H+Q$?A%Y%$$/BXF+,5YW M=@GU7!R6N7QR1'>8,1*5KF9J2_0^6[9&8]$#ZT73N1,^O?G.X\S [XB%;VAY MYN]G7Q2=W.\O7+//GQ/&]_D.?)0>-Y/7. BQ2=JS7E@>@G.C!? ^D+X>'D_B M(/V \FCI3_3N^ME_7#9:#$B8&^]B159/ M(O"/N)^ST&RUOO^&Z<4'!58_(R?%89^5OE'9S;OU)S-^];&(.8:[P*'Y"!HU M 7;$;Z.Z+.3-!2V3Z&PVZ8N62[P0HSV:HBQOM1LO[DL'\J5*6^6(G<3D9N[ MC8 BMW]CX:( &<8!,S&C%!7':6RU&P#BIMCJB8ZMGJ2QU9NH[(E\3JY]+5]R;F"4 3);W 7T\)2SJ7/37#J)D@#K: M-=E!LM0V"UB(=FU.QX2[+O!>'RT-C+[QWNL 9][ # (MYSP M*/9%I(8RU.J&5-B!P ,G*<@PQS+UKL5'.D+3$1'MF>_I_( S.;4Z"<"@"6O! M$-(2(1\$9[W$?0$NF $Z&>)BORKZTOM4^U-OLI'; .G'BT#'K],Z\ 0,3\GA]&\%[[ Y)3PY2QNZ4R\$&A*D=T3,+$AGK1R M60UW9R?LP)PD7(4^P?G!PP>L@2F:B_6S. )5$.,&[H@K&QSGU/]9"NQ28'_@ M%5EYUY9N*$R-'TB/3'HR^YR$);#"2\@':B(!D,V>'3E^O^ M*C:D?PJ_:>-NEHRE8B>2<@0%ZE9!ZZ6\+>7MA:W(RKN/]5J[V\ +_RY/?$QH MI(O\'%+5HJ!?E+$J_B%]^/B+C&(\DYZB1Y0C??:[?A:Z6$E"XGTXC-C*DV'@ MWSI14SJ%.Z?IV<0T/;_^4MY:W[M;JIZ9;95:&&JE$N(NUE<>V\,7/B/ $.RC M<$-0=7B3D!:ZC45A '-TXB@X?:(E.Y>+;'FXZ\4IDH6K]K1PW;D[5S>Y1?$\ MLH7=/[^>5J+G51!=\@&G'9.%1*?I)2"I4\?@%1HLGCO&[;*%E1AYP"R/RYN( MCW43\1FDWCK\W&@4OP'@,&4O/Q\=U)K[]=W[U0!Y&,9\Q-N<*^_FUZ9S H&U MFF*\'8V%I-AE"2JI#ANX,F,>.44W"$XQ5*<+L?6$S3$;RDSM/<42GV)X -U M&X.'%.OM,,Q#%/CF8ABE3(GU[6\\RN-1D<8DMC'/ I4&'*0WMP5J#X6%K!*% M")'J^9'B<@.EVAJ58YX1'4G^W14R:1DL--+ MI#A1RB\"Y)F[,O^GLO1/F,@BB:>Y02-=R)6HB9SQ.? 5$@4GW3,VYK$HC/I%/E(I?#M*ZMCWA!N,7Z M%;I=L2J5S8W-RH-?"UTO7W[ULUJ]_+O*)=="KXQ"+,8Y>+KSA$\QOYN(P,.! M%5T&&H'*DAP(4;B?8/*M2PAR:Y]MX6I^>^HXW?2?U5=HJ 6F9&V\7A)X\03> /H">3?ASW*3[D$OGSP/??DBM>6/SF2+ M$N976SM6!0,\K] +O\D:+U!/;Q@]/5>1+)?VODN[O6%MZZ7=M#8?B!=/!5P[3;" SGIA?4E^GI^?+M'0V_ MMJSJ$GX]R.KN6*42K>Z.57[4U:U:6QI^K;\<^/6R[<8SL!75I:UXCKRV0%NQ MH;7)EK53>EQ;4;4VM:W86;KJ#^6J6SL;J:UXU-6M6F6T%5@IZE%. SU)O??S M_]W_2L==?GKSJS5X;7S^&?&[#?E.P[T_V>]#95T!3:C;%D!;T-GD9\&FE9^- M3=G,JN=*TD7<5V[JF-M4DI^[F+T,T6A">9GQFCVKP> X M +0V?+'+ID=AV>_L5=DJ[YI8.:4R\8(A]TO6:G[VHJ$D(2Q6! ML?P:%IU3TC&10+RFY+IXG3"^;4:=]*CF>]HG:19<-I)+/@L(C5%!:X,VS"0H2MVVL MZDHE:D>$Y$RAVP>6J$MHJNL1WE7.@$21"+%>.=U^#!PB4*HSIM42J?KT&1WL MP&KWXX -@P0)1ME(LJOA_CUE/46"]7E6$>1;Q[C_6AH_SY3YN M3;IE/>O;**G:^];G+OO4^MCLM)HI$^MW3ZRL:O'\^[4%8$Z\,RJ!<]@ RY(, M=79OJ1%^/X#Y\92M1[*'&:)(#A0FKXGD2)MC+,<^+=IJ+DBC/1Y@"@J\*\SC M:7W1X81TDH>);.(A]UD9E-L$E)^B\0PY#(:#=J.,-Z="A"P4 :9E&&..-A C M06D/$1!C=_J=BO$]WI:6?="+7=2-&+ NZX MDV*/H](S)+#Q4K.MI9C&9=Y[,H[UT#2,QQK:D>#V\**P+',NW'M\-\RY\%"" M0U@S#E;F67HQ]:+::VJ<\/&K6FOM'M08[KMAMPBK9AI$P-J:0WRN^\&5SQF^E\2&T68WYV>Q>_0#+K7QIT MT),WY=QP,! %_U",Z]QQ9/[)Q$6'@ M2SJWL X[7M@E+9CFFDB_+4#S,!8;%)YQR+-RZ5=-R%1$HR$X$IJ(4?M<.Q:P MRSY.B?15BL(Q(0@9:DIFDOU&89:]Q,T*N%]TL(BEGAN,_R/PW'0ZFU_2"4T\6?QQ]D'F))K1DV&**:5\@<^@$/E-:F*0R M3&'%'M(E&&36NAN< %[0 0T'-9A#V@?W8"F@3669TYS*4Y4[1R]O198_S(?1T^,-'2JV^$C3*[4 M$WUR0D!E]V"J@I+1XCP?>!%#L!P>*.R$PN$LE"$&-N\:XJ#M!:"8 HZU8UH; M+T3UB&O*<,O!>$<.X$0W"&FAR-3!DR&!.PHT9=R%/M>GY2N?" MPDY'@$J;IN0ZP2I+P.P= 2!5QT8:\&>@Q:B-BL=C-0U[RSL[&]#Y /J Y@N( M&=%Q(["&+M] [=Z)@2^LWAUWG0VE^@GB\!07HSK%8$^FQ^%CTL: #0NIYLZK MG +SJ) M"P,-\>GW/8RB(/%U?8S!A P3(5:,4:,.2O!AH7$OH,8(X[/:#NN: MYY>L36;ALD^T8TQ!'E1EY#S$!,KM>&JBS#1U,-5B1WVFF9PP EI[X"\F+./TCU/4]TA;!^A M]4T?@QGWH\#3(#8_7@H@1,%WK7-I_'.MH$7IA_7SLR,Q9K\ *Q$;+P1#?)[4 M4:Y=,X,T;YV![3E/$'6\R7?'!F[00U;(DM6I!!.IZBB< FNC(;>31#QO(X(D MILA3@0WPMH8.=W![.D70(P!HU3M-1A6E9X7A2F>04=&/1$MV C M7[KN=)D]3,>8YE5T- !1NEBA/03BX-9,E(33,9A=$YIXYKZD[%O );X$')I8 M$/Y$G($ZB*<_(U4C=1P&7#C,C80>K&&%"^1-Z7KGI$F%^T ,1',!EF7,LCFF MJYMN)3$2 R*W\GK:8#F@H,@24;[!(-#::?A?V"'CZ 3T=9>7>]IS0"O+1WH8W \T2DO1'3 M"CK7.#(*^YU)12HVG>_,7#!BIZ>^=TX8]<>H(F244ID<9,."LY@,&S*]]Q/4 M,2E[&ET,2TU,>;Z7'/=F18TOQFOV0 []!'D%#"!,Q9%8ZP@3G I2B%HX"YIY M?-)Q090&.4E?Y*1Q+ULPD55,BL!9H$)*Z&5 $VFR4.P,FIBN,,)8ZC*_-*1= M]IC*52\$5A.1PHV^S%!3V/><2LJS1DXMIOV!NV.H;;M<>GKITG7CNB@\NI(N M'Z?*C4:E4Z/EQ "\DNP9HUCS>Q,180A<'.!K!UNG79?9[0N*[Q":P0E,AR(Q MB#+D(SP2;J)1.EP,'!03+9&;3*K82.4"P-3PC!BJK/SK% P >HIS3&?6V+AM M1I&8J)9.;ZLF2J>2Q0:1X@!;M/7<0YI@ EIT-.T(T("?,7)^3-)W\ #4!+5 M?LVP=(DDQQ%,>T1*W)5F^\<1T*(,SX6MR.(5SMG)J0DPZN]").JR%+8UWT?S MKI,%H)$X1.Q7+A7_R(H2]:5"A8*;8 P6 F9Z(&SA]:"WRDZ!54I9+EG'<#<) M2&KU;1X:C&00Z[X&30@AF@$(=#L%E]@WX:6&P4N=BUC6SYHY@J]8N:;! SLT M:C]]4,XW=Q31 Z&#-A&V2!>&]6?JD,VAPI]9%.Y\2RKI*?%/@JL(S9!'2B'MPK'8_'%BR9!(PA?O>_6Z#8[Q6,("P4X=H!+Q!RO025UOS)Y1 >#(@C-)O)J7<&JHJ?ZI.- MB#V,)J#2UO1Z^J@UO]=IOF^:>LQ/:2\O"1V-7JX:T3ETAO9Z)@@5S;H/VLYE MH$)9MZ9J^>)AX>7^\LO+Z;_X9-4+"("DO'7GM*G/E ZWC'3MS ^5G%!,:!_1 M$R"=:R,P=TY4>\]AIH'7BR-]6[M:9:O'-[S_\0!#N9\R MR.?77M]>9+:6&V0-?_[8ZC_I&SPL]NZ_;]>&L>>^^W]02P,$% @ &$". M4(:-@YX4< N>,2 !4 !A,C R,'$Q97AH:6)I=#DY,BYH=&WL?6U[XL:6 M[>=[?T5=3IQQYL%8$N]VQ\]#,.EVIFUW ">3^29#V6@B)$82[7A^_2U)X,9& MN.U"@GI9YSG'IWF1T-IKU:Y=57M7??A_Y]?=X5]?>F0235WRY>:7SQ==4CHZ M/OZSVCT^/A^>DT_#R\^D5C%,,@QL+W0BQ_=L]_BX=U4BI4D4S4Z.CQ\>'BH/ MU8H?W!\/^\?QK6K'KN^'M#*.QJ6S__LA?NOL__Z?#Q-JC]G__Y\/_^_HB)S[ MH_F4>A$9!=2.Z)C,0\>[)W^.:?@W,_F-R(E<>M;[9^+<.M&'X_0E^['CQ:]]N/7'CV\T^2QT_I>>F,8L.HV?GEUY]L$FGCUEUX:]>K76 M_:7[:\=H-.K-:KUUWNNUJ_5>M]/YI5YK-4IG'XYM]K_DJI4?=1V/'DUH#./$ MM(R#TXC^$QW9KG/OG;CT+EK_Y0_Q.UG/['@3&C@95RR,0-KMBO7A./YX3P_R MX38XD_,!1DR1-,BXX&-V;?)Z]0<\/YC:[NGR MFLB?Q;?\)[YE9-^ZE(RHZRX^_;EDE)+7X

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end XML 19 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover
Apr. 14, 2020
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Apr. 14, 2020
Entity Registrant Name Johnson & Johnson
Entity Incorporation, State or Country Code NJ
Entity File Number 1-3215
Entity Tax Identification Number 22-1024240
Entity Address, Address Line One One Johnson & Johnson Plaza
Entity Address, City or Town New Brunswick
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08933
City Area Code 732
Local Phone Number 524-0400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000200406
Amendment Flag false
Common Stock, Par Value $1.00  
Entity Information [Line Items]  
Title of 12(b) Security Common Stock, Par Value $1.00
Trading Symbol JNJ
Security Exchange Name NYSE
0.250% Notes Due January 2022  
Entity Information [Line Items]  
Title of 12(b) Security 0.250% Notes Due January 2022
Trading Symbol JNJ
Security Exchange Name NYSE
0.650% Notes Due May 2024  
Entity Information [Line Items]  
Title of 12(b) Security 0.650% Notes Due May 2024
Trading Symbol JNJ
Security Exchange Name NYSE
5.50% Notes Due November 2024  
Entity Information [Line Items]  
Title of 12(b) Security 5.50% Notes Due November 2024
Trading Symbol JNJ
Security Exchange Name NYSE
1.150% Notes Due November 2028  
Entity Information [Line Items]  
Title of 12(b) Security 1.150% Notes Due November 2028
Trading Symbol JNJ
Security Exchange Name NYSE
1.650% Notes Due May 2035  
Entity Information [Line Items]  
Title of 12(b) Security 1.650% Notes Due May 2035
Trading Symbol JNJ
Security Exchange Name NYSE

XML 20 a2020q1cover_htm.xml IDEA: XBRL DOCUMENT 0000200406 2020-04-14 2020-04-14 0000200406 jnj:A0.250NotesDue2022Member 2020-04-14 2020-04-14 0000200406 jnj:A1.650NotesDue2035Member 2020-04-14 2020-04-14 0000200406 jnj:A1.150NotesDue2028Member 2020-04-14 2020-04-14 0000200406 jnj:A0.650NotesDue2024Member 2020-04-14 2020-04-14 0000200406 jnj:A5.50NotesDue2024Member 2020-04-14 2020-04-14 0000200406 us-gaap:CommonStockMember 2020-04-14 2020-04-14 false 0000200406 8-K 2020-04-14 Johnson & Johnson NJ 1-3215 22-1024240 One Johnson & Johnson Plaza New Brunswick NJ 08933 732 524-0400 false false false false false Common Stock, Par Value $1.00 JNJ NYSE 0.250% Notes Due January 2022 JNJ NYSE 0.650% Notes Due May 2024 JNJ NYSE 5.50% Notes Due November 2024 JNJ NYSE 1.150% Notes Due November 2028 JNJ NYSE 1.650% Notes Due May 2035 JNJ NYSE